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Genomic structural variations (SVs) are generally defined to include insertions, 
deletions, duplications, translocations, copy number variations and inversions. As with other 
types of variations, inversions are of great significance for studying disease susceptibility, 
population diversity and human evolution. For the last few years, inversions have drawn 
increasing attention with the large amount of data produced by high-throughput sequencing. 
In this dissertation, we defined micro-inversions (MIs) as inversions with the length shorter 
than 100 bp and larger than 10 bp. Until now, there is still a lack of systematic analysis of MIs 
due to the following reason. The unmapped reads are usually completely discarded by previous 
SV detection tools and these unmapped reads may include SVs, mainly consisted of small-
scale MIs, which could cause the reads to fail to map to the reference genome. Fortunately, 
the MI detection tool (MID) which used unmapped reads to detect MIs, was developed by our 
lab in recent years and made the MI analysis available. In this dissertation, we made a 
comprehensive systems biology analysis of MIs on both healthy genomes at the population 
level, and cancer genomes based on the MIs detected from high-throughput sequencing data. 
Specifically, we have accomplished the following two aspects of work: 
(1) Based on the healthy individual genomes from the 1000 Genome Project (1KGP), 
we detected abundant MIs from 1,937 samples in 26 populations all over the world, built a 
landscape of MIs on non-disease individuals, and made a comparative analysis of MIs in non-




Browser Database. Specifically, we discovered 6,968 MIs in human individuals with MID and 
24,476 MIs in non-human primates including chimpanzee, gorilla, orangutan, gibbon, baboon, 
rhesus monkey, and squirrel monkey with searchUMI tool. The MI results in human genomes 
showed that MIs were rarely located in exon regions and the gene density might affect the MI 
distribution among chromosomes. Among the five super-populations, African had the most 
MIs and East Asian had the least, which was consistent with previous research on single 
nucleotide polymorphism (SNP). Furthermore, the average MI number among the five super-
populations were in linear relationship with the descending order: Africa > America > Europe > 
South Asia > East Asia, and this descending order also coincided with the “Out of Africa” 
hypothesis, which assumed that humans originated in Africa and migrated to other continents 
later. Besides, Africans had the most MIs in common with non-human primates, which also 
supported “Out of Africa” hypothesis. The results of phylogenetic tree and PCA not only met 
our expectation but also reflected a regional pattern among the 26 populations suggesting that 
ethnic groups that live geographically closest to one another have a relatively small MI genetic 
distance. In addition, the cluster of MIs in the human populations also coincided with human 
migration history and ancestral lineage. Thus, we proposed that MIs were potential 
evolutionary markers for investigating population dynamics. In general, we made a 
comprehensive analysis of MIs in human genomes and our results revealed the diversity of 
MIs in human populations and showed that they were related to evolution, environmental 
adaptation, and health. These MI results may further support for the analysis of human genome 




(2) Base on the cancer genome data from sequence read archive (SRA) database, we 
further detected and analyzed the MIs of 451 samples in six cancers, including esophageal 
cancer, bladder cancer, hepatocellular carcinoma, lung cancer, prostate cancer, and pancreatic 
cancer. We also used the 1,937 healthy individuals from 1KGP as control samples. We first 
analyzed the distribution of MIs among chromosomes in genomes of six cancers. The results 
showed that there were both similarities and differences in MI distributions among 
chromosomes in different cancers. We also found that the MI number in cancers was much 
higher than that in healthy samples. Besides, prostate cancer had the most MIs and 
hepatocellular carcinoma had the least. Moreover, we analyzed the genes with frequent MIs 
in six cancers. It showed that the genes in which MIs frequently appeared in different cancers 
were specific, and many of these genes were closely related to cancers. In addition, we 
compared the MIs we detected with the SNPs reported previously and found that 132 SNPs 
overlapped with MIs. In summary, our analysis of MIs in six cancers showed that the number 
of MIs in different cancers, as well as chromosome and gene preference, were different. The 
divergent MIs among six cancers may provide help for personalized diagnosis and therapy of 
the six cancers in the future.  
In conclusion, based on the high-throughput sequencing data, we focused on studying 
the small-scale micro-inversions (MIs), which have been ignored for a long time, and made a 
comprehensive bioinformatics analysis of large amounts of MIs in human genomes. The 




genetic diversity and evolution. At the same time, through the comparative genomics analysis 
of MIs in different cancers, we hope to provide further understanding for precision medicine 





CHAPTER 1 INTRODUCTION 
This chapter intends to introduce the motivation and background of this dissertation, 
which is mainly about micro-inversions (MIs) analysis in human genomes. As an important 
type of genome structural variations (SVs), MIs play important roles in disease susceptibility, 
population diversity and human evolution. Herein, we first give an introduction to SVs and 
MIs, and also describe the current research status about SVs and MIs. Since all the data we 
used for analysis in this dissertation are the whole genome sequencing (WGS) short reads 
based on high-throughput sequencing, we then give an introduce to the characteristics of the 
WGS short reads produced by high-throughput sequencing from 1000 Genome Project (1KGP) 
and Sequence Read Archive (SRA). As we used MID and searchUMI as the detection tools 
for identifying MIs, we finally give a brief description of the challenges of MI detection and 
introduce these two MI detection tools. 
1.1 Introduction to structural variations and micro-inversions 
1.1.1 The definition and research status of SVs  
Structural variations (SVs) are one of the most important mechanisms that account for 
genetic diversity [1]. In addition, amounts of studies have shown that SVs account for the most 
important mechanism of evolution [ 2 - 6 ]. Generally, SVs include deletions, duplications, 




SVs generally include balanced variations and unbalanced variations[8]. The standard of 
classifying balanced variations and unbalanced variations is to see whether the sequence 
length changes after the variation. The length of sequence with balanced variations does not 
change after variation such as inversion and translocations, while the sequence length of 
unbalanced variations increases or decreases after variation such as insertions, deletions, 
duplications and CNVs. 
Specifically, the insertion means that the individual genome contains a sequence that does 
not exist in the reference gnome; the deletion means that the individual genome missed a 
sequence on the reference genome; the copy number variation (CNV) or the duplication means 
that the individual genome contains multiple copies of a sequence on the reference genome; 
the inversion means that the individual genome contains a sequence that is the reverse 
complementary sequence on the reference genome. The specific details of the SVs including 
insertions, deletions, translocations, duplications, copy number variations (CNVs) and 
inversions are shown in Figure 1.1. 
Statistical data show that SVs are quite heterogeneous in size, ranging from a few base 
pairs to several mega bases. The high-throughput sequencing provides sequencing reads of 
100 bp which are much shorter compared with the reads of 700 to 1000 bp in Sanger 
sequencing. In fact, as one of the most important genome variations, SVs account for 1.2% of 
all the genome variations while the most studied single nucleotide polymorphisms (SNPs) 




simultaneously may cause very complex genome rearrangements[10]. SVs have been proven to 
be related with many diseases such as neurocognitive disorder, infantile autism, schizophrenia, 
colitis and cancer [11-14]. Numerous studies have shown that inversions as one of the important 
SVs, play significant roles in cancer susceptibility and human evolution[15]. 
 
Figure 1.1 –  Different types of SVs including insertion, deletion, translocation, 
duplication, copy number variation (CNV) and inversion. A, B, C, and D represent 
four consecutive DNA segments. E represents a DNA segment that is not consecutive to 
A, B, C, and D. “-B” in the schematic diagram of Inversion indicates a reverse of the 
original sequence segment B. 
In the past few years, the studies of SVs have made a lot of progress with the advent of 
high-throughput sequencing[16]. Meanwhile, high-throughput sequencing also brought new 
problems and challenges. Indeed, high-throughput sequencing has provided plenty of data for 




high speed and low cost of high-throughput sequencing have made huge amounts of individual 
genome sequencing data available. 
 By now, a few world-wide genome sequencing projects have been finished including 
1KGP[18] and sequence read archive (SRA) databases[19]. These worldwide individual genome 
sequencing projects provide the possibility to better analyze the variation of the human 
genome structures. Moreover, these databases including 1KGP and SRA database are also 
beneficial to further understanding of human disease and precision medicine.  
The study of gene variation started from 1936, while the research on human genome 
variation did not appear until 1977[20]. With the development of high-throughput sequencing 
technologies during these years, the analysis of SVs has been promoted fast and steadily. 
Additionally, high-throughput sequencing has provided plenty of data for studying 
metagenomics, protein binding regulation, gene function annotation, and multiple diseases 
including cancers [21-23].  
Over the past decades, there have been growing interest in studying SVs of different 
scales[24,25]. Zhang et al. studied genome variations with different length size including SNPs 
(1 bp), fine-scale SVs (50 bp-5 kbp), intermediate-scale SVs (5 kbp-50 kbp), large-scale SVs 
(50 kbp-5 Mbp), and chromosomal SVs (>5 Mbp)[26]. Different scale of SVs have their own 
characteristics and affect the gene function in various aspects. Also, with the advent of high-
throughput sequencing, a number of SVs databases began to appear, which summarized the 




The effect of SVs on human genomes was first observed in healthy human individuals[27]. 
However, SVs have been proven to be related with various diseases including autism, 
schizophrenia, regional enteritis and cancers [11-14]. Specifically, Brandler et al. have proven 
that SVs are closely related to patients with autism[28]. Besides, some studies have showed that 
familial Parkinson's disease is caused by SVs in special genes, though most Parkinson's 
patients are sporadic[29,30]. In addition, Lakich et al. found that an inversion in VIII gene could 
cause hemophilia A and this inversion existed in about 43% of type A hemophilia patients[31].  
SVs could generally account for the genetic diversity among different populations and 
affect gene expression in various ways. Some SVs could affect gene expression quantity by 
inserting or deleting some sequence copies such as insertions, deletions, and tandem 
duplications, while the other small-scale insertions, deletions or inversions may alter parts of 
gene sequences, thus cause damage of exons, alternative splicing and gene fusions[32].   
As for the SVs in non-coding regions, they may influence regulatory elements and further 
affect gene function or signal pathways, Although SVs exist in many genes, it is reported that 
genome rearrangements especially the deletions are likely to lead to purifying selection or 
negative selection. Purifying selection or negative selection is the selective removal of alleles 
that are deleterious during evolution process[33]. Researches show that the genes enriched with 
SVs involved in many biological activities such as immune response, drug metabolism, signal 





The SV databases provide supports for the study of SVs and deeper understanding of the 
population genomes. However, these databases have the problem of incomplete and 
inconsistent SV information due to the fact that most SVs are obtained through different tools 
and experiments. Since there is currently no general guideline or tool for evaluating these SV 
sites, these SV-site information may not be absolutely reliable to a large extent. 
 Furthermore, the studies about the analysis of the common or overlapped SVs among 
different genomes are lacked. This lack of SV studies indicates that people’s understanding of 
genomic SVs is still limited. Undoubtedly, future researches are needed to yield a more 
accurate and reliable database of such SV analysis among different genomes. To achieve this 
goal and to enrich disease-related genomic structural variation, future researches need to focus 
on how to construct a credible, accurate, genome-level overview of the human genome SVs.  
Among all the various types of SVs, insertion and deletion are the most studied types, 
and the researches of deletion and insertion are also the most abundant in human genome 
sequences including in the cancer genomes[36-39]. In recent years, analysis regarding to the 
effects of copy number variations (CNVs) on genomes have been intensively studied[40,41]. 
However, as a balanced variation of SVs, inversions have not been studied a lot due to the 
detection difficulty. Thus, inversion occurrences and the effect of inversions are difficult to 
observe clinically unless they fall on gene regions or regulatory regions on the genome. 
Therefore, the comprehensive analysis of inversions is more urgent than other types of SVs. 




An inversion is defined as a sequence reversal on the chromosome segment. Generally, 
SVs occur in different scales from a few base pairs to several mega bases[42]. In this dissertation, 
we analyzed micro-inversions (MIs) shorter than 100 bp and larger than 10 bp, which is 
defined in a previous work of our lab[43]. Inversions are an important type of genome variations, 
which are conductive to study human genomics and cancer genomes[44]. However, little is 
known about the fine-scale inversions, MIs, due to the limitation of tools of MIs until the MI 
detection tool, MID, was developed in a previous work by our lab [43]. 
Figure 1.2 shows the schematic diagram of an MI detected with the human assemble hg19 
as the reference genome. In this dissertation. This MI occurred in gene ANKRD36 on 
Chromosome 2 from 97,826,002 to 97,826,027. So far, numerous studies have focused on the 
inversion diversity in human [45,46]. Since three decades ago, easily detectable macro-inversion 
polymorphisms in human have been verified by experiments and were implicated in discovery 
of human evolutionary history [47-48]. Flores et al. (2007) located three chromosomal inversions 
in tissue of human through frequent repeated DNA fragments undergoing non-allelic 





Figure 1.2 - One example of MI occurring in gene ANKRD36. This MI occurred on 
Chromosome 2 from 97,826,002 to 97,826,027. 
With the development of sequencing techniques, the identification of inversion 
polymorphisms within species has been greatly promoted [50-52]. Cáceres et al. was able to 
precisely classify individuals in the population based on inversion status [53].The inversions 
located in 8p23.1, which are associated with autoimmune and cardiovascular disease [54], are 
indicated to be an evolutionarily marker in perceive of human phenotypic diversity [55 ]. 
Navarro et al. (2003) proved that large inversions might play a significant role in speeding up 
of the speciation of human and chimpanzee [56]. Osborne et al. demonstrated that a 1.5 million 
inversion commonly exist in families with Williams Beuren syndrome [57]. However, such 
studies on human inversions merely allowed the determination of variants of several kilo bases 
to mega bases due to the backwardness of experimental techniques [58-61]. 
In recent years, among all kinds of inversions, the small-scale inversions especially MIs 
with length of 10 to 100 bp have drawn increasing attention in the studies of SVs. Figure 1.3 




individual genomes from 1KGP reported by by He et al [42]. Both of genes PREPL and SLCA1 
are reported as strongly related genes for Hypotonia-Cystinuria Syndrome (HCS) [62].  
 
Figure 1.3 - An MI occurring in the 3’ UTR region of gene SLCA1 and PREPL1[43]. 
This MI was found in 46 human individual genomes and some non-human primate 
genomes. 
Besides, this MI existed in 46 individual genomes belonging to 14 different populations 
including JPT (Japanese in Tokyo, Japan), CEU (Utah Residents (CEPH) with Northern and 
Western Ancestry), FIN (Finnish in Finland), GBR (British in England and Scotland), TSI 
(Toscani in Italia), IBS (Iberian Population in Spain), CLM (Colombians from Medellin, 
Colombia), MXL (Mexican Ancestry from Los Angeles USA), PEL (Peruvians from Lima, 
Peru), PUR (Puerto Ricans from Puerto Rico), ACB (African Caribbeans in Barbados), ASW 
(Americans of African Ancestry in SW USA), LWK (Luhya in Webuye, Kenya) and YRI 




individuals from East Asia, ten individuals from Europe, 12 individuals from America and 22 
individuals from Africa. This MI existence in such many populations and continents implies 
the ubiquitous trend of MIs in human genomes. 
 
Figure 1.4 - An MI that alters six amino acid in gene OR51I1 [43]. The six altered amino 
acids were located in the fourth transmembrane domain, which is less conserved than 
the extracellular regions. 
As shown in Figure 1.3, at the same position with this MI on the chimpanzee genome and 
the Neanderthal genome, there was an almost identical sequences to the MIs found in the 46 
human individual genomes. This result was likely to indicate that the reference human genome 
assemble hg19 has recently undergone this MIs compared with the corresponding sequence of 
the most recent common ancestor of human, chimpanzee, and the Neanderthal. However, the 
MI shown in Figure 1.3 was marked as multiple nucleotide variation by the existing genomic 
structural variation database (GeneBank: rs71416108) [63]. This result indicates that MIs may 
have been improperly reported as SNPs previously. We will further discuss the association of 
MIs and the SNPs proved previously in Chapter 3. It also implies that the understanding of 




huge room for improvement, which is also the significance of the study on MI analysis in this 
dissertation. 
Another MI which altered six amino acids in the gene OR51I1 was displayed in Figure 
1.4[43]. The six altered amino acids were located in the fourth transmembrane domain, which 
is less conserved than the extracellular regions. Thus, the changes in these amino acids may 
have serious effects on health.   
 
Figure 1.5 - An MI that alters three amino acid in gene PSRC1[43]. This MI interrupted 
the region boundary of gene PSRC1 and altered three amino acids in the coding region. 
As is shown in Figure 1.5, an MI interrupted the region boundary of gene PSRC1 and 
altered three amino acids in the coding region [43]. It should be noted that the PSRC1 gene 
encodes a protein rich in proline, which is the regulatory target of p53. The MI occurrence in 
cancer- related genes may indicate the MI influence on cancer genome. 
 An MI occurring in the CDS region of gene JMJD4 and the 5’ UTR region of the gene 
SNAP47 is shown in Figure 1.6[43]. Specifically, this MI alters five amino acids of JMJD4 
gene, which as a number of the Jmjc-domain-only families only contains JmjC domain. The 




with cancer diagnosis. Besides, the SVs in genes included in this family and the corresponding 
changed gene expression are reported to be associated with cancer regulation. Thus, this 
specific MI found in the CDS region of JMJD4 gene may help further understanding the 
association of this gene and the diagnosis as well as treatment of related cancers. 
 
Figure 1.6 - An MI that alters five amino acids. This MI occurrs in the CDS region of 
gene JMJD4 and the 5’ UTR region of the gene SNAP47 [43]. 
Despite the clear evidence showing the direct relationship of MIs and cancers, the results 
above show that some MIs do overlap with CDS regions and regulatory regions, which may 
have an influence on human health. As for the MIs in intron regions, although the functions 
of these introns affected by MIs are not understood yet by now, we believe that these MIs will 
benefit studies of relation of variation and health in the future. Besides, the MIs shared only 
by a specific population especially those overlapped with gene regions, may increase the 
susceptibility of some disease. However, further sophisticated genetic and experimental data 
are necessary to confirm this point. 
The high-throughput sequencing provides pair end sequencing reads of 100 bp which are 
much shorter compared with the 700 to 1000 bp in Sanger sequencing [17]. In this dissertation, 




[43], which is similar to the length of short reads produced in high-throughput sequencing. With 
the rapid development of high-throughput sequencing technology, plenty of short reads have 
raised new challenges for studying different-scale SVs especially MIs. For examples, MIs may 
cause sequence mismatches resulting in sequence assemble errors. Besides, inversions may 
have relation with gene evolution, genetic polymorphism and human health. Furthermore, 
compared with those large-scale inversions, MIs are more likely to occur [70]. Therefore, it is 
significant to explore the MIs and carry the comprehensive MI analysis. 
1.1.3 The research status of MI studies 
The result of numerous studies on human genome SVs indicates that, inversions as one 
of the most important types of SVs, have played a significant role in genetic diseases, cancer 
genomes, and human evolution[64,65]. However, inversions as a type of balanced variation, will 
not cause the DNA sequence length increase or decrease. Thus, it is hard to find out the direct 
impact of inversions unless they are located in genetic regions or regulatory regions[66]. In fact, 
very limited inversions are discovered on human genomes until 2005[67]. Later, the high-
throughput sequencing and the high-quality human assembles have made the imbalanced 
variation inversion analysis possible for the reason that the reliable human assemble have 
provided more precise and stable standard for SV detection.  
Unlike other SVs such as CNVs, deletions, and insertion, the analysis of inversions has 
been overlooked. Around 80% of deletions were reported to be included in the studies of SVs 




all archives of SVs from the databases of dbVar [68] and DGVa [69] exhibit an undeniable lack 
of recording inversions, particularly for micro-inversions (10 bp to 100 bp). This is not 
consistent with the inference proposed previously that smaller SVs are much more common 
than larger ones in the human genomes[ 70 , 71 ], which indicates that a majority of small 
inversions are possibly kept to be detected and analyzed. 
 
Figure 1.7 - All records on SVs from databases of dbVar and DGVa[72]. The records 
exhibit a lack of recording inversions, particularly for micro-inversions (10 bp to 100 
bp). 
During the process of SV detection and sequencing alignment, the sequencing short reads 
which cannot be mapped to the reference genomes are called unmapped reads. Generally, these 
unmapped short reads are completely discarded by previous SV detection tools and will not 




Actually, these unmapped sequencing reads may include SVs, mostly MIs, which could cause 
those reads to fail to map to the reference genomes. Due to the lack of alignment between 
these unmapped short reads and the reference genome, MIs have not been detected by other 
tools previously, let alone the MI analysis. We will further discuss the challenges of MI 
detection below. 
In fact, people are not sure about how many inversions really exist definitively and how 
these inversions distribute. Besides, there is not a definite conclusion of the effect of MIs on 
human diseases [66]. Since the studies of MIs are very constrained, the mechanism of MI how 
MIs happen is not clear to researchers due to the following reasons. First, the high-throughput 
sequencing provides plenty of individual short reads, while the detection tools and analysis 
methods need to be changed to adapt such short reads. Second, MIs are balanced variations 
and most have not caused fatal damage to the genomes, which made the analysis of MIs 
extremely complex[73]. Last but not the least, there’s not a reliable detection tool for identifying 
MIs until the MID [46] tool was developed by our lab.  
Our analysis of MIs on actual genetic data including samples from 1KGP and SRA 
databases can fill the gap in the field of MI research. To better understand MIs, we included a 
comprehensive analysis of MIs with both healthy samples from 1KGP and cancer samples 
from SRA database. From the analysis of MIs in 1KGP and the comparison genome analysis 




population and ancestry scales. Besides, we obtained MI difference among different cancer 
genomes with data from SRA database. 
1.2 The characteristics of the sequencing technologies 
The current researches on SVs including our MI studies relies heavily on sequencing 
technologies. Furthermore, both the detection and analysis methods will change intensively 
with the rapid development of sequencing. In this dissertation, both the individual sequencing 
short reads used are whole genome sequencing (WGS) based on high-throughput sequencing. 
Besides, our understanding of MIs will alter with the development of sequencing technologies. 
The wide applications of high-throughput sequencing techniques have brought both problems 
and challenges to the studies of SVs including MIs. Based on this point, the sequencing 
technologies are of great importance. Thus, we would like to describe the characteristics of 
the high-throughput sequencing and WGS in this part. 
1.2.1 The advantages and challenges brought by high-throughput sequencing 
From the Sanger sequencing method, which appeared in the 1970s[ 74 ], to the rapid 
development of high-throughput sequencing technology in recent years, genome sequencing 
technology has been developed by leaps and bounds[75]. At the same time, the sequencing 
technology also greatly affects the study of SVs including MIs.  
The working principle of Sanger sequencing is to segregate the sequence randomly into 




amplification to obtain enough sequence contents to be recognized by terminal staining. The 
first whole genome of human genomes was sequenced with Sanger sequencing technology[76]. 
The length of reads generated by Sanger sequencing are between 700 to 1,000 bp. This kind 
of sequencing is repeated several times to reach the required sequencing depth, which is the 
ratio of the total number of sequenced base pairs to the whole size of the sequenced genome[77]. 
However, the genome coverage by Sanger sequencing is usually not high, which makes the 
detection and analysis of SVs not convenient. 
The mainstream sequencing technology currently is the high-throughput sequencing 
technology, of which the complete sequencing process includes building templates, 
sequencing imaging, data analysis and other steps[78]. In the sequencing process, complete 
DNA sequences are first broken up to screen for segments of a specific length (typically 100 
bp). Then a sequence of tens to hundreds of base pairs is read from one end or both ends of 
each fragment. Although the length of each read is short, high-throughput sequencing 
technology can read a large number of such short sequences at the same time. This process 
makes the total length of all short sequences reach several to ten times of the length of the 
sample DNA, thus making it possible to obtain the high-coverage sample DNA sequence and 
detect SVs more effective. 
In the high-throughput sequencing, the method of reading sequences from both ends of a 
fragmented DNA fragment is called pair-end sequencing. All the short reads used for analysis 




stranded sequence, and the sequencing process consists of two directions starting at the 5' end 
of each strand of DNA. In the process of pair-end sequencing, the short reads are all paired, 
which could provide more information than single-end sequencing. Since the pair-end 
sequencing reads uses DNA fragments in two directions and there is an insert between the two 
ends, they are more widely used in detection of SVs especially the large-scale ones which can 
take good advantage of the insert size between the two ends. 
The greatest advantage of the high-throughput sequencing technology is that it can obtain 
a large number of sequencing data in a short time. Therefore, there is a great improvement in 
sequencing time and material consumption in high-throughput sequencing compared with 
Sanger sequencing. The high-throughput sequencing platform depends on Implantable cyclic 
arrays to complete sequencing process. These arrays allow to produce at most millions of DNA 
sequencing reads at the same time. The plenty of high-throughput sequencing reads make the 
mass of SV researches possible.  
The high-throughput sequencing has provided abundant data for metagenomics, protein 
binding regulation, gene functional annotation and gene structural variation[79]. Furthermore, 
the high speed and low cost of high-throughput sequencing has made massive individual 
sequencing data available. Accordingly, plenty of individual sequence databases have begun 
to emerge such as the 1000 genome project (1KGP) [18], and sequence read archive (SRA) 
databases [19]. These databases provide the possibility to better analyze SVs in human genomes 




However, the low coverage of some high-throughput sequencing data based on whole 
genome sequencing also increases the difficulty of MI detections. Most SV detection tools 
required the input file of sequencing short reads with sufficient coverage such as NA12878 
released by 1KGP, which is widely used as a standard individual genome by SV detection 
evaluation and analysis. The SV detection results of NA12878 are also regarded as the gold 
standard of SVs (annotated data set) as a result of its high coverage sequencing. Despite of 
this, the sequencing coverage of the pair-end reads in the individual genome NA12878 is only 
15x.  
However, the actual situation is that except for a small number of high coverage 
individual genome samples, most of the genome reads in 1KGP are in low coverage of 2~4x. 
Few SVs detection methods can obtain satisfactory SV results with such a low-coverage data 
due to the limitations of the algorithm in using feature signals, such as the algorithm based on 
feature signals of read depth. But fortunately is, MI Detection Tool (MID) developed by our 
lab could take full advantage of these low-coverage individual genomes and still get a high 
sensitivity in detecting MIs. We will go into a deep discussion of the MID in the following 
parts. 
The regularly used high-throughput sequencing platforms include Roche/454, Illumina, 
SOLID, Polonator, and HeliScope. These platforms differ in key sequencing processes and 
the corresponding sequencing reads [78]. However, the sequencing reads produced by these 




platforms. Specifically, the sequencing reads produced by Illumina platform, used in this 
dissertation, are shorter than 100 bp which are called short reads. Hence, large amount of short 
reads produced by high-throughput sequencing, which have a high sequencing errors, need a 
new comprehensive analysis. Besides, the short length of the high-throughput sequencing 
brings new challenges in the detection of SVs, especially those extremely small scale SVs. 
Taking the personal genome sequencing data of 1KGP as an example, Illumina sequencing 
insert size in 1KGP is 100 to 600 bp, which greatly exceeds the length of MIs, which are 
generally 10 to 100 bp, so the pair-end mapped reads are not suitable for MIs detection in short 
reads under high-throughput sequencing. 
1.2.2 The characteristics of whole genome sequencing (WGS) 
Generally, WGS produce the complete DNA of the whole genome at a single time. WGS 
brings about sequencing of the genome chromosomal DNA along with DNA encompassed in 
the mitochondria[80]. WGS is often understood to be used to determine the human genome, but 
the scale and flexibility of the high-throughput sequencing is such that it can be used efficiently 
in any species, such as animal husbandry, plants, disease-related microorganisms and non-
human primates[81-83].  
Thus, whole genome sequencing is the most comprehensive approach to genome research. 
Genomic information could be used to identify genetic diseases, find mutations that drive 




and the increased ability to process large samples of data have made whole-genome 
sequencing the most powerful tool available to today's sequencers.  
However, WGS has its own limitation. For example, WGS is time consuming and the 
cost of WGS is really high compared with whole exome sequencing (WXS)[86]. Besides, since 
the WGS needs to cover all the sites on the genome, the sequencing depth is usually not high.  
At the same time, the low coverage of the high-throughput sequencing data also increases the 
difficulty of MI detections. Most SV detection tools required the input file of sequencing short 
reads with sufficient coverage, while the actual situation is that except for a small number of 
high coverage individual genome samples, most of the genome reads in 1KGP are in low 
coverage of 2~4x. Few SVs detection methods can obtain satisfactory SV results with such a 
low-coverage data due to the limitations of the algorithm in using feature signals, such as the 
algorithm based on feature signals of read depth.  
Interestingly, the low-coverage sequencing genome data, which do not meet the 
requirement of many previous SV detection tools, are able to be used by MID. We will discuss 
this in the following parts. In this dissertation, all the data including the samples from 1KGP 
and SRA databases are whole genome sequencing. Although these data are in low coverage, 
the reliable detection of MIs with MID gives us a thorough landscape in both gene regions as 
well as the intergenic regions of human genomes.  




1.3.1  The challenges of detecting MIs based on short reads 
The advent of high-throughput sequencing has provided large amounts of short reads data 
to the SV analysis. However, the detection tools of the small-scale MIs are still constrained 
mainly due to the following reasons. 
Most of the current existing SV detection tools rely on the first step of the sequence 
mapping. For example, the broadly studied database 1KGP used the sequence mapping tool 
Burrows-Wheeler alignment (BWA)87 to first map the individual short reads to the human 
reference assemble to lay foundations for next steps such as SV detection. As the most widely 
used sequence alignment tool, BWA is designed based on the classic algorithm of Smith-
Waterman. However, the Smith-Waterman algorithm could just simply deal with single-base 
mismatches and small-scale insertions or deletions, which are collectively referred as indels.  
Nonetheless, the short reads in which MIs exist may fail to map to the reference genome. 
Generally, the sequencing short reads that are not able to map to the reference genome are 
called unmapped reads. During the mapping procedure, BWA attempted to reprocess these 
unmapped reads that could not be successfully matched in the first round by setting higher 
error rates for these reads. Nonetheless, they still could not handle the problem of mismatches 
caused by MIs. Thus, these unmapped short reads which include MIs are not be able to be 




Considering the reason described above, these unmapped short reads are usually 
completely discarded by alignment and mapping tools and are not processed later. Thus, the 
large amount of information that may be carried on the unmapped short reads is simply ignored 
by subsequent analysis tools and studies. Accounting that these unmapped short reads are not 
able to map to the reference genome, they do not contain important mapping information such 
as matching locations needed for the next SVs detection analysis. Therefore, most existing 
tools for analyzing SVs are not able to process these unmapped reads well. In fact, these 
unmapped reads may include SVs, possible mainly MIs, which cause these reads fail to map 
to the reference genome. In other words, if MIs could be found accurately, it is possible to find 
information carried in these reads that are ignored by other SV detection tools. However, For 
example, about 3% of the short reads in the individual genome NA19917 with the low-
coverage sequencing from the publicly available database 1KGP are unmapped reads.  
Besides, MIs are a kind of micro-scale structural variations, which are characterized by 
their short length and the complex detection from short reads. The length of short reads 
produced by the high-throughput sequencing makes it extremely difficult to determine MIs. 
The SVs detection tools such as CNVnator [88], which use read depth as the detection feature, 
have difficulties detecting MI events of such a small scale without being certain about 
breakpoints, thus have a low sensitivity. Besides, such detection tools are limited by the quality 




detect, those SV detection tools based on the feature signal of read depth are mostly used to 
detect deletions and CNVs and are not suitable for detecting MIs shorter than 100 bp.  
Additionally, the SV detection tools based on the feature signal of read pairs such as 
DELLY[89] and those based on split reads such as Pindel[90] are not suitable for MI detection 
in short reads for the reason that the size of the SVs that such tools can detect depends on the 
insert size between paired-end short reads. Taking the personal genome sequencing data of 
1KGP as an example, the Illumina sequencing insert size in 1KGP is 100 to 600bp, which 
greatly exceeds the length of MIs (generally 10 to 100 bp), so they are not suitable for MIs 
detection in short reads based on high-throughput sequencing. In addition, SV detection tools 
based on the feature signal of read pairs are very insensitive to SVs with a size as small as MIs, 
because they have difficulties distinguishing small disturbances from normal background 
changes with read pair spacing. 
At the same time, the low coverage of the high-throughput sequencing data also increases 
the difficulty of MI detections. Most SV detection tools required the input file of sequencing 
short reads with sufficient coverage such as NA12878 released by 1KGP, which is widely 
used as a standard individual genome by SV detection evaluation and analysis. The SV 
detection results of NA12878 are also regarded as the gold standard of SVs (annotated data 
set) as a result of its high coverage sequencing. Despite of this, the sequencing coverage of the 
pair-end reads in the individual genome NA12878 is only 15x. However, the actual situation 




genome reads in 1KGP are in low coverage of 2~4x. Few SVs detection methods can obtain 
satisfactory SV results with such a low-coverage data due to the limitations of the algorithm 
in using feature signals, such as the algorithm based on feature signals of read depth.  
Studies have shown that population-level sequencing data can provide evidence of low-
frequency SVs as well as more materials of relation between SVs and phenotypes [ 91 ]. 
Therefore, as for the amounts of low-coverage sequencing data from 1KGP we analyzed MIs 
at the both population-scale and ancestry-scale level by fusing the MIs in multiple individual 
genome samples in this dissertation. In this way, the integrated analysis data of MIs is more 
reliable compared those obtained at individual level. 
Another difficulty of MI detection is the high false positive for the reason that there may 
be other multiple types of SVs around MIs in short reads, which may interfere with locating 
breakpoints and determining MIs events. Although MIs themselves as on kind of balanced 
variation, do not affect the length of the genome sequence, the other types of variations 
including SNVs, small indels, unbalanced SVs including insertions, deletions, duplications 
and CNVs, and other types of SVs including translocations may occur simultaneously in the 
MI regions and on the same short read. 
In summary, MIs play significant roles in human genomes as discussed in the previous 
section, while MIs are still poorly understood by studies. The previous SV detection methods 
and tools have their own limitations on MI detection owing to such small scale and the 




genomes which are gathered by long contigs, the situation is much simpler. However, the 
mainly used sequencing reads in SV detection are the short reads which may not be simple to 
assemble. Despite the fact that the high-throughput sequencing has provided plenty of 
individual genome data, the personal genome database represented by 1KGP mostly provide 
low-coverage short reads which make MI detection challenging.  
To solve the problems above, Micro-inversion Detector (MID) was developed by our lab 
in recent years. Besides, MID is the first known tool to perform MI detection analysis with 
unmapped short reads produced by high-throughput sequencing.  
1.3.2 SearchUMI: detecting MIs from assembled genomes 
Different with the lack of MI detection based on high-throughput sequencing, a few MI 
detection tools based on assembled sequences or the alignments against a reference genome 
have been proposed. Among of them, the MI detection tool SearchUMI [92], identifies MIs 
from the pair alignments of non-human primates against human reference genome hg19. 
In this dissertation, for the seven non-human primate assembles, we applied the tool 
searchUMI, to detect MIs from the alignments between the human and seven non-human 
primate genomes. SearchUMI is able to identify inversions ranging from 5 to 125 bp, which 
is the approximate length of MIs. To make a better comparative analysis of MIs in human and 





SearchUMI identifies MIs from the pair alignments of non-human primate assemble 
genomes against hg19 in two steps: deciding the variation-rich genome regions and 
investigating the reverse locations from these variation-rich regions. The variation-rich 
regions are the regions where the gaps and mismatches are originally identified as a threesome 
of the closest gaps and mismatches that are nearer than supposed on the alignment. In case of 
that a gap or mismatch is discovered, the locations of the neighboring gaps and mismatches 
are locked. Finally, the reverse sequences are identified from these regions after discussion of 
each situation. 
 
Figure 1.8 - An inversion of 4 bp found in gene PTPRB in alignment of chimpanzee 
assemble and human reference identified by searchUMI. The numbers represent the 
exon counts. The blue represents the MIs. The red box represents the alignment details 
of chimpanzee, human, gorilla, and orangutan[92]. 
It is reported that the PPV for searchUMI is more than 99.98 for detection of MIs in the 




composition. The performance of searchUMI in the assemble alignment of non-human 
primates indicate that the MI results are credible. An inversion found in the pair alignment of 
chimpanzee and human altering two amino acids is shown in Figure 1.8. The inversion exist 
specifically in chimpanzee but not in gorilla or orangutan indicate MIs may have an effect on 
evolution in chimpanzee lineage. Thus the detection and analysis of MIs are of great 
significance. 
Generally, SearchUMI is able to detect MIs from the alignments between the human 
reference genome assemble hg19 and seven non-human primate genomes including 
chimpanzee, gorilla, orangutan, gibbon, baboon, rhesus monkey, and squirrel monkey. 
Considering that the assemble of the non-human primates are more representative and 
comprehensive than any single primate individual, the comparative MI analysis between 
human and non-human primates are more convincing. 
1.3.3 Micro-inversion detection (MID): detecting MIs from short reads 
As described above, those unmapped short reads are usually completely discarded by 
alignment and mapping tools and are not processed later. Thus, the large amount of 
information that may be carried on the unmapped short reads is simply ignored by subsequent 
SV detection tools. In this dissertation, we used MID [43], which was proposed in a previous 
work of our lab in 2016, to detect MIs in both samples of healthy and cancer gnomes. Actually, 
these unmapped sequencing reads may include SVs, most likely mainly MIs, which could 




unmapped reads and the reference genome, MIs have not been detected by other tools 
previously, let alone the MI analysis. 
 MIs are hard to detect and analyze due to their extremely short length compared with 
other kinds of SVs. In fact, the MI detection limitations of the previous SVs detection tools 
are mainly reflected in a few aspects. Firstly, most of the previous SV detection tools are 
insensitive to MIs, which is mainly because the length of MIs is too short. Besides, the MI 
detection process is also more complicated than that of other SVs. Secondly, many of the 
widely used personal genome sequencing data for SV detection are of low coverage, while 
most of the SV detection tools require high-coverage sequencing data. Finally, there may be 
other types of SVs around MIs on the same short read, which makes MI detection more 
difficult. 
The previous work in our lab proposed MID (http://cqb.pku.edu.cn/ZhuLab/MID), which 
was the first tool to make use of unmapped reads that are ignored by other SV detection tools 
to detect MIs[43]. MID is able to match the fragments flexibly and deal with such problems as 
fragment overlaps and multiple breakpoints during MI detection process. In the MI detection 
process, MID initially remaps the unmapped reads onto the human reference assemble hg19 
[116] by anchoring a sequence alignment. Then, MID gets all possible sequences matching 
fragment sets by a series of process including the fusion of k-mer, neighboring sub-sequence 
sets, removing the overlapped sequences and scoring these sequences. Among of these 




palindromic sequences or other mismatches. Finally, MID adopts dynamic algorithm to select 
the final optimum solution and outputs the reverse sequence information into the final output 
file. The pipeline of MID is shown in Figure 1.9.  
 
 
Figure 1.9 - The pipeline of MID [43]. The process of detecting MIs mainly includes 
inputting, anchoring and mapping, path-finding and MI detection, and reporting MIs. 
MID generally outputs the MI information including the original short read name, 
chromosome, MI start coordinate, MI end coordinate, strand direction, MI length, and the 
specific sequence of MIs. The detailed information of the output file of MID is shown in Figure 
1.10. In fact, there is no gold standard of human reference due to the genome polymorphism 




which are assembled by several individual genomes, are used as the alignment reference. Thus, 
MID also uses the hg 19 as the reference against the studied individual genomes to decide the 
exact MIs.  
MID has a high accuracy and reliability when detecting MIs with the average sensitivity 
(SN) of 80.4% and Positive Predictive Value (PPV) of 90.2% in simulated sequencing data. 
Besides, MID performs well in both low-coverage and high-coverage sequencing reads. 
Moreover, MID also performs stably in the simulated data consisted of MIs as well as a 
mixture of other types of SVs. These results indicate that MIs detected by MID are reliable 
and believable. In general, MID is the first MI detection tool which used unmapped reads to 
detect MIs, and made the MI analysis on human genomes in this dissertation available. 
 
Figure 1.10 - The format of the output file with detailed alignment information by MID 
[43]. This output file mainly includes the original short read name, chromosome, MI 
start coordinate, MI end coordinate, strand direction, MI length, and the specific 
sequence of MIs. 
1.4 Introduction to the contents of this dissertation  
SVs in human genomes have been studied extensively. However, little is known about 
the role of micro-inversions (MIs), generally defined as small (10 to 100 bp) inversions, 




ethnically diverse populations is demanding for interpreting human evolution history, 
determining the appropriate design and giving us insight into genetic disease-related studies. 
This dissertation is organized as follows: 
Chapter 1 gives an overview of structural variations (SVs) and micro-inversions (MIs). 
With the advent of high-throughput sequencing, a large amount of high-throughput sequencing 
databases have emerged including 1KGP and SRA databases. These data provide possibility 
for the comprehensive analysis of SVs and the study of diseases. In this dissertation, MIs are 
defined as inversions shorter than 100 bp and larger than 10 bp. MIs are an important type of 
SVs, while the analysis of MIs is still lacked. Thus, this dissertation focusing on the MI 
analysis of both health samples and cancer samples is of great significance. 
Chapter 2 describes the MI analysis in individuals from 1KGP. We explored the 
distribution of MIs in 26 human populations and seven non-human primate genomes, analyzed 
the phylogenetic structure of the 26 human populations based on MIs. We further investigated 
the functions of MIs located within genes associated with human health. The analyses of MIs 
in human genomes showed that MIs were rarely located in exon regions. The MI analysis of 
non-human primates and human populations was consistent with the “Out of Africa” 
hypothesis. The cluster of MIs in the human populations also coincided with human migration 
history and ancestral lineage. Thus, we proposed that MIs were potential evolutionary markers 




populations and showed that they were related to evolution, environmental adaptation, and 
health. 
Chapter 3 describes the MI distribution among six cancers from SRA database. To 
expand our knowledge of the roles of MIs in cancers, we analyzed the MIs of 451 samples 
from six cancers, including esophageal cancer, hepatocellular carcinoma, lung cancer, 
pancreatic cancer, prostate cancer, and bladder cancer. We also used the 1,937 samples from 
the 1KGP as the control samples. We further analyzed the distribution of MIs in the six cancers 
among 24 chromosomes. Besides the chromosome preferences, different cancers also have 
different preferences for various genes. We also calculated the average number of MIs per 
individual among each cancer. The MI preferences for divergent genes among six cancers may 
provide a guidance for the treatment and therapy on the six cancers.  





CHAPTER 2  MICRO-INVERSIONS WITH CLUE TO 
POPULATION GENETICS ANALYSIS IN HUMAN GENOMES 
 MIs, as one of the most important SVs, may play important roles in human evolution, 
environment adaption, and health. This part describes the analysis of MIs in healthy human 
genomes on both the super-population and population scales. Our analysis of MIs with 1KGP 
data will improve our understanding of human genetic diversity and human evolution. The 
comparative analysis of MIs from the scale of populations, super-populations, and species will 
be the keystone of further implementation of human evolution theory. 
2.1 Introduction 
As a kind of SVs in genomes, inversions are defined as a chromosome reversal where a 
sequence segment ends upside down [52]. Usually, an inversion appears when a chromosome 
endures breakage and displacement within itself. Although it has been long known that 
inversions are associated with primate evolution [93], only recently they are found to play an 
important role in human evolution and diseases along with the wide applications of high-
throughput sequencing techniques [94,95]. A number of studies have focused on inversions in 
the human genome [96] and for decades many detectable macro-inversion polymorphisms in 
humans have been verified by experiments and implicated them in human evolutionary history 
[97,98]. For example, inversions located in 8p23.1, which are associated with autoimmune and 




phenotypic diversity. Besides, a common 900-kb inversion polymorphism at 17q21.31 
associated with Parkinson’s disease suggesting multiple distributions of inversions among 
ethnic populations [95]. Indeed, with the developing of inversion detecting methods, inversions 
have been studied as one of the most important mechanisms accounting for genetic diversity. 
However, the studies mentioned above were mainly limited to detecting the large-scale 
inversions, usually >100 kb. Recently several studies began to put more efforts using small-
scale inversions with size much shorter than 10 kb into exploring such as phylogenetic 
problems. These studies found an influence of small inversions on forming unusual flanking 
sequences in human and chimpanzee genomes [101] and developed tools to detect pico-in-place 
inversions [102]. Nevertheless, their results have large discrepancies because of their non-
uniform definitions based on the size of small inversions [43]. Moreover, current studies 
concentrate mainly on the small inversion differentiation of human (Homo sapiens) and 
chimpanzee (Pan troglodytes) genomes [101], while excluding the out-group primate genomes 
such as gorillas (Gorrilla ), orangutans (Pongo pygmaeus), gibbons (Hylobates sp.), baboons 
(Papio anubis), and rhesus monkeys (Macaca mulatta) et al. 
Of all inversions of small size, MIs, a type of extremely small inversions (generally 10 
to 100 bp) found remarkably in human genomes, are uncertain with their function for the 
research community. However, statistical analysis implied that MIs, usually like other rare 
genomic changes, may serve as excellent phylogenetic markers because of their rare 




of MIs among multiple non-primate species such as yeast[ 104 ], sticklebacks[ 105 ], 
grasshoppers[ 106 ], drosophila[107 ], ducks[108 ], chicken[109 ], avian[ 110 ], and mice[111 ]. As for 
primates with larger genomes, comparative studies of the influence of chromosomal inversions 
occurring within or between chromosomes in the human and chimpanzee genomes can be 
traced back to the last century. Nevertheless, such studies on human inversions are limited 
because of the limitations of the detection techniques [112]. With the advent of high-throughput 
sequencing, 1KGP has provided a large number of WGS reads of healthy individuals on a 
large scale of populations across the world[114-116]. However, the short reads generated from 
high-throughput sequencing in the 1KGP data are generally <100 bp, which length are too 
short, leading to both the detection and analysis of the MIs difficult. Unlike the well-studied 
large inversions, which are easily detected, MIs have not yet been studied because it is difficult 
to detect MIs shorter than read length, most of which are identified as unmapped reads and are 
thus completely discarded. The MID[43] method, developed in our previous study, relies on 
unmapped reads for detecting MIs and performed well. The algorithm of MID is designed 
based on a dynamic programming path-finding approach which can efficiently and reliably 
identify MIs from unmapped short next-generation sequencing reads. This subsequently 
facilitates the analysis of MIs across a great scale of populations based on high throughput 
sequencing data. Therefore, an increased understanding of the MI landscape across various 
human races will lead to comparative analyses among individuals, ultimately providing 




Although efforts have been devoted to analysis of small inversions in non-human 
creatures, there are not yet comprehensive studies of MIs, which are <100 bp, on human 
diversity, evolution and diseases in a large number of human genomes. In this study, we set 
out to detect MIs and further investigate the roles of MIs in the diversity and evolution of 26 
human populations and seven non-human populations. Overall, we explored the distribution 
of MIs in all 26 populations from the 1KGP, and detected 6,968 MIs within all 1,937 human 
samples and 24,476 MIs in seven non-human primate genomes. From the detected MIs, we 
analyzed the extent of diversity of MIs and built phylogenetic trees by MI counts from both 
the scale of population and species. These results indicated that MIs rarely occurred in or 
nearby a protein-coding gene, and only a few were common in both primates and human 
populations. They also show that Africans share the most common MIs with other non-human 
primates, a finding that may provide evidence of the “Out of Africa” hypothesis [113]. More 
importantly, the phylogenetic analysis demonstrates that MI is a sensitive evolutionary marker 
for categorizing all populations. The categories coincide with human migration history and 
ancestral lineage. The analysis also implies the function of some MIs located within disease-
causing genes. Thus, it is concluded that MIs should merit our attention for the studies of 
human evolution and environmental adaptation. 





This part mainly introduces the datasets we used for the MI analysis of human and non-
human primate genomes from 1KGP and UCSC Genome Browser. 
1KGP is a genome sequencing project that aims to provide comprehensive personalized 
sequencing data of human genomes and construct the map of human genome SVs. 1KGP 
sequenced thousands of individuals from different countries and nationalities around the world 
and got a massive amount of personalized genomes. In 2012, 1KGP committee first released 
both the read sequencing and SVs of 1,092 individuals around the world[114]. Three years later 
in 2015, 1KGP released the recent SV results of 2,054 samples[115].   
The recent samples in 1KGP are from 26 populations around world. They are CDX 
(Chinese Dai in Xishuangbanna, China), CHB (Han Chinese in Beijing, China), CHS 
(Southern Han Chinese), JPT (Japanese in Tokyo, Japan), KHV (Kinh in Ho Chi Minh City, 
Vietnam), BEB (Bengali from Bangladesh), GIH (Gujarati Indian from Houston, Texas), ITU 
(Indian Telugu from the UK), PJL (Punjabi from Lahore, Pakistan), STU (Sri Lankan Tamil 
from the UK), CEU (Utah Residents (CEPH) with Northern and Western Ancestry), FIN 
(Finnish in Finland), GBR (British in England and Scotland), IBS (Iberian Population in 
Spain), TSI (Toscani in Italia), CLM (Colombians from Medellin, Colombia), MXL (Mexican 
Ancestry from Los Angeles USA), PEL (Peruvians from Lima, Peru), PUR (Puerto Ricans 
from Puerto Rico), ACB (African Caribbeans in Barbados), ASW (Americans of African 




Gambia), LWK (Luhya in Webuye, Kenya), MSL (Mende in Sierra Leone), and YRI (Yoruba 
in Ibadan, Nigeria). 
Indeed, 1KGP classified all the 26 populations according to their ancestry lineage into 
five super-populations including East Asia, South Asia, Africa, Europe, America. Specifically 
CDX, CHB, CHS, JPT, and KHV are classified into East Asian Ancestry (EAS); BEB, GIH, 
ITU, PJL, and STU are classified into South Asia Ancestry (SAS); CEU, FIN, GBR, IBS, and 
TSI are classified into European Ancestry (EUR); CLM, MXL, PEL, and PUR are classified 
into American Ancestry (AMR); ACB, ASW, ESN, GWD, LWK, MSL, and YRI are classified 
into African Ancestry (AFR). Among these samples, 1,937 samples which are found with MIs 
are included for analysis in this dissertation.  
The SV polymorphism across all the 26 populations released by the 1KGP Consortium 
is shown in Figure 2.1. The size of each pie chart is proportional to the population 
polymorphism in the corresponding population. Each pie chart is divided into four parts: the 
private deep color represents SVs private to this population; the private light color represents 
SVs private to this continent; light grey color represents SVs shared across the continent where 
the population resides in; deep grey color represents SVs shared across all continents. Our 
results on MI analysis also show that some MIs are shared among the five super-populations 
and the other MIs are private to one specific super-population or private to a population. In 
general, each population has both private MIs and common MIs shared with other populations 





Figure 2.1 - SV polymorphism shown from 1KGP. The size of each pie chart is 
proportional to the population polymorphism in the corresponding population. Each 
pie chart is divided into four parts: the private deep color represents SVs private to this 
population; the private light color represents SVs private to this continent; the light 
grey color represents SVs shared across the continent that the population in; the deep 
grey color represents SVs shared across all continents[116]. 
In recent years, there have emerged many researches focusing on SVs using 1KGP data. 
Trevor et al, have used 1KGP data to explore the relationship between deleterious variations 
and disease risks [117]. Ting et al studied APOL gene variation and the haplotype diversity with 
1KGP data [118]. The study by the 1KGP Consortium shows that abundant SVs are located in 
gene regulatory regions including untranslated regions (UTRs), promoters, enhancers, 
insulators and transcription factor binding sites (TFBS) [116].  
The variant site number per genome of the 26 populations is displayed in Figure 2.2. It 
shows that the variation number of different populations varies a lot, which also coincides with 
our MI result. In this dissertation of MI analysis, we also find that the populations of African 
ancestry including ACB (African Caribbeans in Barbados), ASW (Americans of African 




Gambia), LWK (Luhya in Webuye, Kenya), MSL (Mende in Sierra Leone), and YRI (Yoruba 
in Ibadan, Nigeria) have high MI occurrence frequency. This result also supports the “Out of 
Africa” hypothesis [119]. Moreover, the populations mixed with multiple ancestry lineages tend 
to have more MIs compared with those with single ancestries. The variation number from the 
1KGP shown in Figure 2.2 displays that ASW which have American and African ancestry 
have very high variation frequency. Besides the variation number in the populations of 
American ancestry including CLM (Colombians from Medellin, Colombia), MXL (Mexican 
Ancestry from Los Angeles USA), PEL (Peruvians from Lima, Peru) and PUR (Puerto Ricans 
from Puerto Rico) rank only second after African populations. These could also be due to the 
African ancestry of these American populations.  
 
Figure 2.2 - The variant site number per genome of 26 populations from 1KGP[116]. 
To elucidate the features of MIs among human genomes, we collected WGS BAM files 
of the unmapped reads of 2,427 samples from the most recent version of the 1KGP [116].  1KGP 




and laid a solid foundation for SV studies. Moreover, the data of 1KGP has been widely used 
in the exploration and researches of SVs. However, there have not been studies about MIs with 
1KGP data. Due to the limitations of current sequencing technology, sequencing time and 
sequencing cost, the coverage of most individual genome data is still very low. Among them, 
the average coverage of individual low-coverage genome sequencing data is 2x~4x. These 
low-coverage data have provided both chances and challenges for the analysis of MIs. 
Fortunately, MID could take good advantage of these low-coverage data and detect important 
MIs. 
Then, MID was used to deal with all the low-coverage unmapped short reads using human 
assemble hg19 as the reference genome and gave a list of the detailed MI information. Of all 
the 2,427 samples, 490 did not contain MIs and were excluded. The included 1,937 samples, 
which covered all of the 26 populations, were categorized into five super-populations: East 
Asians [CDX (Chinese Dai in Xishuangbanna, China), CHB (Han Chinese in Beijing, China), 
CHS (Southern Han Chinese), JPT (Japanese in Tokyo, Japan), and KHV (Kinh in Ho Chi 
Minh City, Vietnam)], South Asians [BEB (Bengali from Bangladesh), GIH (Gujarati Indian 
from Houston, Texas), ITU (Indian Telugu from the UK), PJL (Punjabi from Lahore, Pakistan), 
and STU (Sri Lankan Tamil from the UK)], Europeans [CEU (Utah Residents (CEPH) with 
Northern and Western Ancestry), FIN (Finnish in Finland), GBR (British in England and 
Scotland), IBS (Iberian Population in Spain), and TSI (Toscani in Italia)], Americans [CLM 




PEL (Peruvians from Lima, Peru), and PUR (Puerto Ricans from Puerto Rico)], and Africans 
[ACB (African Caribbeans in Barbados), ASW (Americans of African Ancestry in SW USA), 
ESN (Esan in Nigeria), GWD (Gambian in Western Divisions in the Gambia), LWK (Luhya 
in Webuye, Kenya), MSL (Mende in Sierra Leone), and YRI (Yoruba in Ibadan, Nigeria)]. 
The sample number of each population used in this dissertation is displayed in Figure 2.3. 
Besides, the details of all samples from 1KGP are listed in Appendix A. 
For further comparative analysis between humans and other primates, we also 
downloaded the human reference genome assembly hg19 [116] and the pairwise alignment data 
of seven non-human primates from the UCSC Genome Browser Database [ 120 ] 
(http://hgdownload.soe.ucsc.edu/downloads.html). The UCSC Genome Browser Database 
include a broad collection of vertebrate and model organism assemblies. On June 22, 2000, 
UCSC and the other members of the International Human Genome Project consortium 
completed the first working draft of the human genome assembly, forever ensuring free public 
access to the genome and the information it contains. A few weeks later, on July 7, 2000, the 
newly assembled genome was released on the web at http://genome.ucsc.edu , along with the 
initial prototype of a graphical viewing tool, the UCSC Genome Browser.  
In this dissertation, we included assemble alignments from seven non-human primates 
including chimpanzee, gorilla, orangutan, gibbon, baboon, rhesus and squirrel monkey. Since 
the assembly of each primate is gathered from several individual genomes, the assembled 




are many versions of each primates, we listed the assemble version for each primate here. We 
used the data version panTro4 for the human/chimpanzee alignment, gorGor3 for the 
human/gorilla alignment, ponAbe2 for the human/orangutan alignment, nomLeu1 for the 
human/gibbon alignment, papHam1 for the human/baboon alignment, rheMac3 for the 
human/rhesus alignment, and saiBol1 for the human/squirrel-monkey alignment from the 
UCSC genome browser (http://genome.ucsc.edu/). The detailed information of the seven non-
human primate assembles is shown in Table 2.1. The columns of Primate, Synonyms, 
Coverage, Sequence length, Scaffolds, and Contig represent primate names of the alignment, 
the synonyms of the alignment version, sequencing coverage depth, the total sequence length 
of the alignment, the number of scaffolds used for the assemble alignment and the number of 
contigs respectively.  
2.2.2 MI detection and annotation 
To detect MIs from the 1KGP data, we applied the software MID[43] with default 
parameters and mapped all unmapped sequencing reads to the human assembly hg19. The 
choice of MID was prompted by our previous investigation that MID is capable of efficiently 
identifying MIs from unmapped short reads through inversion reading and reference genome 
mapping. MID could give the list of MIs and detailed information of each MI including 
chromosome, MI start coordinates on the chromosome, MI end coordinates on the 




same MI occurring in multiple short reads of the same individual was counted as one during 
MID detection.  
Table 2.1 - The seven non-human primate assemble alignments. 
Primate Synonyms Coverage Sequence 
length 
Scaffolds Contig 
Chimpanzee panTro4 6x 3,309,561,368 27,002 183,859 
Gorilla gorGor3 2.1x /35x 3,029,537,234 53,823 461,501 
Orangutan ponAbe2 6x 3,437,863,358 79,309 408,185 
Gibbon nomLeu1 5.6x 2,936,035,333 17,968 17,968 
Baboon papHam1 High 
coverage 
/ / / 
Rhesus rheMac3 50x 2,969,971,616 38,224 448,689 
Squirrel 
monkey 
saiBol1 80x 2,608,588,537 2,686 151,414 
After detecting MIs, we annotated them with the gene via the GENCODE database[121], 
GENCODE is a genetic annotation database that identifies genetic characteristics through a 
series of computational analyses, manual annotations, and experimental results. GENCODE 
integrates a lot of gene information such as protein coding, long noncoding RNA (lncRNA), 
coding sequence (CDS) and is widely used in genome annotation. During the process of gene 
annotation, MIs were annotated as intergenic, genetic, exon, intron, CDS and UTR. In case 
that an MI was annotated as intergenic, it means this MI was in intergenic region and didn’t 
overlap with any gene regions; if an MI was annotated as gene, it means this MI was 
overlapped with one gene on the hg19; if an MI was annotated as exon it means that this MI 
was overlapped with on exon of one gene; if an MI was annotated as intron, it means that this 




as CDS, it means that this MI overlapped with coding sequence region of one exon; if an MI 
was annotated as UTR, it means that this MI overlapped with untranslated regions of one gene. 
 
Figure 2.3 - The individual genome number of the 26 populations 
The gene function and the correlated translated protein functions were annotated with 
GeneCards [122] well as Metascape [123]. GeneCards is a searchable, integrative database that 
provides comprehensive information on all human genes. It integrates gene information 
including gene function, the corresponding protein function and signal pathway functions. We 
annotated the private genes of super-populations that MIs were frequently located in with the 
protein function and further explored the gene function and specific health problems. 
Metascape is an online tool for retrieval of gene functions. We used Metascape as a gene 
function supplement to the annotations from GeneCards. 
We detected the MIs of non-human primates by searchUMI tool, on aligned data because 




MIs. During detection, the parameter pd was set at 0.0137 for panTro4, 0.0175 for gorGor3, 
0.034 for ponAbe2, 0.029 for nomLeu1, 0.066 for papHam1, 0.065 for rheMac3, and 0.123 
for saiBol1. Furthermore, based on the definition of MIs in this dissertation, we removed 
inversions that were <10 bp. 
Although the recurrence of specific MIs is rare, a series of MIs often converge to 
particular regions along the genome. To make a more comprehensible analysis of MIs in the 
following sections, by extending the boundaries of overlapping MIs, we defined MI regions 
(MIRs) as the union regions of overlapping MIs and MIRs need to meet the requirement that 
MIRs are at most 4 bp longer than the MIs they contain (shown in Figure 2.4), similar to the 
copy number variation regions (CNVRs) proposed by Yang et al [124]. According to our 
definition of MIR, it turns out that each MI is contained in one and the only unique MIR and 
each MIR may contain one or more MIs. Thus, the MIs contained in the same MIR, have 
almost the same start and end position on the chromosome. 
 
Figure 2.4 - Schematic showing how MIR refers to the region of a union of overlapping 
MIs (green bars, MIR; yellow bars, MIs in one individual). 




In order to analyze the diversity of MIs among all primates from an evolutionary and 
comparative viewpoint, we built matrices with rows denoting MIRs and columns denoting all 
26 human populations. Each element in this matrix represented the sum of MIs included in the 
corresponding MIR within this population. In light of these matrices, we constructed a 
phylogenetic tree with the neighbor-joining algorithm via the R computer language. MIR 
sharing was analyzed by counting the number of shared MIRs among the five super-
populations. The distances used in the neighbor-joining algorithm were Euclid’s distances 
between every pair of column vectors, i.e., the distance between two populations was defined 
as the average of pairwise MIRs between two individuals from the two populations.  
MIR sharing was analyzed by counting the number of shared MIRs among the five super-
populations. The population structure of the 26 populations was visualized through PCA with 
R language to figure out if the distribution of MIs is on account of the geographical locations 
and migration history. In the PCA, we used the same matrix as that for the phylogenetic tree 
analysis. In addition, we regarded 2,140 MIRs as the principle components. 
2.3 Results 
Our previous work (He et al., 2016)[43] has focused on the detection of MIs in the initial 
phases of 1KGP, which is however, encompassed by fewer individuals from only 19 
populations and is largely limited to the statistical analysis of MI distribution, in spite of a few 
disease-related genes analysis. Herein we constructed a more integrated map of MIs including 





Figure 2.5 - Geographic locations of the 26 populations from 1KGP. Different color fills 
represent the five super-populations: Orange, Africa; red America; blue Europe; 
purple, South Asia; green, East Asia. 
Besides, compared with our previous work, this study, made a more comprehensive 
analysis which emphasized the population diversity of MIs, quantified the MI genetic impact, 
and explored the important role that MIs play in human evolution. In this dissertation, we 
included 1,937 samples, which covered all of the 26 populations, categorized into five super-
populations: East Asians (CDX, CHB, CHS, JPT, and KHV, South Asians (BEB, GIH, ITU, 
PJL, and STU), Europeans (CEU, FIN, GBR, IBS, and TSI), Americans (CLM, MXL, PEL, 
and PUR), and Africans (ACB, ASW, ESN, GWD, LWK, MSL, and YRI). 6,968 MIs were 
detected from the total 1,937 samples. Among 6,968 MIs, 1,149 are from East Asia, 1,387 
from Europe, 2,146 from Africa, 850 from America, and 1,436 from South Asia. The 
geographic locations of the 26 populations from 1KGP is shown in Figure 2.5. Different color 




South Asia; green, East Asia. The pie chart of the MIs in five super-populations is displayed 
in Figure 2.6. 
 
Figure 2.6 - Pie chart of MIs of MIs in fiver super-populations. The proportion of MIs 
in East Asia, Europe, Africa, America and South Asia are 16.49%, 19.91%, 30.8%, 
12.2%, and 20.61% respectively. 
2.3.1 Overview and distribution of MIs in 1KGP 
With the MID method, we identified 6,968 MIs in 1,937 samples from the 26 human 
populations, and they were merged into 2,140 MIRs. The Table 2.2 list all the 6,968 MI 
information. The table is organized by populations and super-populations. The columns of the 
table from the left to right represent population or super-population abbreviations, population 
description, number of samples from 1KGP, MIR number, MI number, the number of MIRs 
supported by at least two MIs, the ratio of the number of MIs over the number of samples, 




over the number of all MIRs. As shown in the table, the average MI number of each individual 
is 3.6. Besides, 977 of the 2,140 MIRs (45%) are supported by at least two MIs. 
Table 2.2 - Overview of MIs detected in 1937 samples. 













CHB Han Chinese in Beijing, China 73 119 202 30 2.77 0.25 
JPT Japanese in Tokyo, Japan 90 209 416 61 4.62 0.29 
CHS Southern Han Chinese 80 116 183 27 2.29 0.23 
CDX 
Chinese Dai in Xishuangbanna, 
China 
62 59 99 16 1.6 0.27 
KHV 
Kinh in Ho Chi Minh City, 
Vietnam 
74 176 249 32 3.36 0.18 
EAS East Asia 379 483 1149 166 3.03 0.00 
CEU 
Utah Residents (CEPH) with 
Northern and Western Ancestry 
80 300 387 37 4.84 0.12 
TSI Toscani in Italia 75 137 195 23 2.60 0.17 
FIN Finnish in Finland 77 237 283 18 3.68 0.08 
GBR British in England and Scotland 74 185 251 31 3.39 0.17 
IBS Iberian Population in Spain 70 199 271 31 3.87 0.16 
EUR Europe 376 877 1387 140 3.69 0.00 
YRI Yoruba in Ibadan, Nigeria 50 156 247 33 4.94 0.21 
LWK Luhya in Webuye, Kenya 83 161 278 44 3.35 0.27 
GWD 
Gambian in Western Divisions in 
the Gambia 
102 177 384 65 3.76 0.37 
MSL Mende in Sierra Leone 81 168 316 29 3.90 0.17 
ESN Esan in Nigeria 87 167 347 51 3.99 0.31 
ASW 
Americans of African Ancestry in 
SW USA 
58 149 293 50 5.05 0.34 
ACB African Caribbeans in Barbados 81 152 281 51 3.47 0.34 
AFR Africa 542 634 2146 323 3.96 0.00 
MXL 
Mexican Ancestry from Los 
Angeles USA 
55 93 176 26 3.20 0.28 
PUR Puerto Ricans from Puerto Rico 39 107 220 46 5.64 0.43 
CLM 
Colombians from Medellin, 
Colombia 




Table 2.2 (continued) 
PEL Peruvians from Lima, Peru 63 125 187 22 2.97 0.18 
AMR America 227 347 850 125 3.74 0.00 
GIH 
Gujarati Indian from Houston, 
Texas 
83 108 193 29 2.33 0.27 
PJL Punjabi from Lahore, Pakistan 85 141 351 54 4.13 0.38 
BEB Bengali from Bangladesh 68 131 270 36 3.97 0.27 
STU Sri Lankan Tamil from the UK 91 139 334 51 3.67 0.37 
ITU Indian Telugu from the UK 86 119 288 53 3.35 0.45 
SAS South Asia 413 377 1436 223 3.48 0.00 
Total - 1,937 2,140 6,968 977 3.60 0.12 
Pop, population name; Sam-num, number of samples for the population; MIR-num, number of MIRs in each 
population; MI-num, the number of MIs in each population; Mul-sup, the MIRs supported by at least two MIs; MI-
num/Sam-num, the ratio of the number of MIs over the number of samples, which indicates average MIs per individual; 
Mul-sup/MIR-num, the ratio of multiple MIs supported MIRs over the number of all MIRs. 
The result indicates that MIs are shared by different individuals, populations, and even 
super-populations. In general, Table 2.2 listed the real distribution of MIs among human 
genomes. In this dissertation, MIs are displayed in many levels including short reads, 
individual genomes, population-scale, and ancestry-scale. Furthermore, the MIRs supported 
by multiple short reads, individuals genomes, various populations will contribute to the 
concrete understanding of MIs. 
Among the 6,968 MIs, there are five appearing in more than 200 individual genomes. 
The five high-frequency MIs may exist in many healthy people, which means that these MIs 
may also be considered to be added into the human reference assemble hg19. Since hg19 is 
still not complete, and new-found genome variations are usually added when updating hg19, 




presented in SV studies24. Of the 2,140 MIRs, 1,169 ones (54.6%) overlapped with gene 
regions, of which 1,063 (90.9%) overlapped with intron regions, while notably the rest 106 
with exon regions for gene regions. Of the 106 MIRs in exon regions, 30 (28.3%) overlapped 
with Coding Sequence (CDS) regions, 39 (36.8%) with Untranslated Regions (UTR), and 37 
(34.9%) with other functional regions including miRNA, Mt_rRNA et al.  
 
Figure 2.7 - Scatter plot of MIR count against chromosome length. The numbers from 
1 to 22 and the characters X and Y represent the 24 chromosomes (22 autosomes and 
two sex chromosomes). 
Indeed, the MIs in CDS regions could be important candidates for future studies, for the 
reason that compared with MIs in intergenic regions or intron regions, those MIs in the exon 
regions, especially in the CDS regions, are more likely to change the protein sequence directly 




The scatter plot for MI and MIR count against the length of chromosomes is shown in 
Figure 2.7. Generally, the number of MIs and MIRs are positively correlated with the lengths 
of chromosomes (Figure 2.7), which is reasonable as longer chromosomes has more DNA 
bases, thus have more chances to make an error in DNA replicating. 
Figure 2.8 - Scatter plot of MI and MIR count against gene density. 
Additionally, correlation between MI or MIR count and chromosome length was 
analyzed using Pearson’s correlation analysis. Specifically, strong correlation was detected 
between MIR count and chromosome length, where the Pearson’s correlation coefficient was 
r=0.935 (P<0.0001); the corresponding result for MI was 0.861 (P<0.0001). The scatter plot 
of MI and MIR count against the gene density was also described in Figure 2.8. Although we 
found no strong linear correlation between the number of MIs and gene density, we found a 




chromosomes with high gene density. For example, we discovered that the chromosomes 19, 
17, 16, and 11, of which the corresponding scatters were above the fitting line, have high gene 
density, as shown in Figure 2.8. This suggests that gene density may also affect the MI count 
of a chromosome, while this relationship is not strictly linear. We also displayed the 
distribution of MI and MIR event rate distribution across chromosomes in Figure 2.9. 
 
Figure 2.9 - The distribution of MI and MIR event rate distribution across 
chromosomes. 
The Length distribution of 6,968 MIs and 2,140 MIRs is shown in Figure 2.10. As shown 
in Figure 2.10, the lengths of the MIs varied from 15 to 45 bp, but were concentrated within 
18 to 30 bp. The specific positions of MIs among 24 chromosomes are shown in Figure 2.11. 
It should be noted that comparing the MIs in our study with the inversion-calling results from 




was much larger than 100 bp. We also noted other researches about inversions and no MIs in 
the range of 10 to 100 bp were discussed previously. This suggests that there is no length 
overlapped between MIs in this dissertation and traditional inversions in the previous studies. 
Thus, our analysis on MIs (<100 bp), overlooked by all the studies including the 1KGP 
analysis, will increase our limited understanding of human SVs. 
 
Figure 2.10 - Length distribution of 6,968 MIs and 2,140 MIRs. The length of MIs 
range from 13 to 45 bp and the length of MIRs range from 14 to 45 bp. 
2.3.2 MI count per individual among 26 populations 
SNPs and SVs in the 1KGP have been reported to display various allele frequencies and 
reveal genetic diversity among 26 populations [116]. However, MIs, as a kind of SVs, have 
never been studied to capture the genetic diversity among 26 populations. Thus, we performed 




Figure 2.11 - Distribution of locations of MIs and MIRs on chromosomes. The 
outermost ring coordinates correspond to each chromosome. The number on the axis 
represents the coordinates of the bases on the chromosome in Mbp. The red and blue 
bars represent the MIs and MIRs. 
In view of the fact that the sample number varies by population, diversity is better 
reflected by the average number of MIs per individual among super-populations and 
populations than the total MI number of each super-population and population. To address this 
point, we define parameter 𝐶𝑝̅̅ ̅ to represent the average count of MIs per individual among 






                                                         (1) 
where Ci means the count of MIs per individual, and Np means the total number of individuals 





Figure 2.12 - Error bar plot of average count of MIs per individual among super-
populations with fitted regression line. The data are presented as the mean ± SE. 𝑪𝒑̅̅̅̅  is 
the average count of MIs per individual. Different color fills represent the five super-
populations. Orange, Africa; red America; blue Europe; purple, South Asia; green, 
East Asia respectively. The average count ranged from 3.03 to 3.96. 
From the aspect of the individual, we calculated an average of 3.6 MIs per individual. 
The error bar plot with the fitted regression line for the average number of MIs per individual 
among the five super-populations including Africa, America, East Asia, Europe and South 
Asia was shown in Figure 2.12. Indeed, we numbered the five super-populations, Africa, 
America, Europe, South Asia, and East Asia from one to five and performed Pearson’s 
correlation analysis among the five super-populations. The Pearson's correlation coefficient 




count of MIs per individual among the five super-populations: Africa > America > Europe > 
South Asia > East Asia. This descending order supported the “Out of Africa” hypothesis, 
which believed that humans originated in Africa, then modern Africans migrated to the other 
continents. We will discuss this situation further in the part of Discussion. 
 
Figure 2.13 - Average count of MIs per individual among 26 populations. The average 
ranged from 1.60 to 5.64. 
The MI counts in each individual among the five super-populations, which were used for 
calculating the means and standard errors of MI numbers in five super-populations are the 
number of MIs in each individual. Notably, Africa had the highest count of MIs per individual, 
3.96, and East Asia had the lowest, 3.03. This result is consistent with the recent studies of the 




the lowest SNP number. The average counts of MIs per individual for the 26 populations 
classified by five super-populations, are also shown in Figure 2.13. 
 





Since the average MI count is 3.6 (varied from 1.60 to 5.64, see Figure 2.13) for all 26 
populations, we found that the group with the average MI count over 4.5 consisted of five 
populations: PUR (Puerto Ricans from Puerto Rico, Cp = 5.64), ASW (Americans of African 
Ancestry in SW USA, Cp = 5.05), YRI (Yoruba in Ibadan, Nigeria, Cp = 4.94), CEU (Utah 
Residents (CEPH) with Northern and Western Ancestry, Cp = 4.84), and JPT (Japanese in 
Tokyo, Japan, Cp = 4.62). We noted that the top two populations with high-frequency MIs, 
PUR (Cp = 5.64) and ASW (Cp = 5.05), also have a high degree of admixture in the analysis 
of SNP analysis in the 1KGP study. This suggests a potential influence of ancestral lineage 
mixture on MI counts in populations. We will discuss the five populations in details in the 
section of Discussion and Conclusions. 
In order to examine the genetic structure of MIs hierarchically among populations, we 
constructed a genetic distance-based phylogenetic tree using all of the MIs detected from the 
26 populations (Figure 2.14), which yielded results that generally provide evidence of genetic 
clusters: African and American populations were clustered into one branch, European and 




Figure 2.15 - Phylogenetic trees for the 26 populations based on the MIs in gene 
regions. The average pairwise population distance was computed with the 2,135 MIs in 





Figure 2.16 - Phylogenetic trees for the 26 populations based on the MIs in intergenic 
regions. 




We also performed phylogenetic analysis with MIs in gene regions only to construct a 
phylogenetic tree (Figure 2.15). Similar to the full MI analysis in Figure 2.15, the phylogenetic 
analysis with MIs in gene regions in Figure 2.15 displayed similar cluster into four branches. 
Besides, we used MIs in intergenic regions only to construct a phylogenetic tree (Figure 2.16). 
As shown in Figure 2.15 and 2.16, the populations were more dispersed in phylogenetic tree 
with MIs in intergenic regions compared with that in gene regions. 
 
Figure 2.17 - PCA of 26 populations. The results are plotted as the first and second 
principal components. Different color fills represent the five super-populations: 
Orange, Africa; red America; blue Europe; purple, South Asia; green, East Asia.. 
The topology of the phylogenetic tree not only met our expectation but also reflected a 
pattern among the 26 populations suggesting that ethnic groups that live geographically closest 




in Finland) population (Clustered with the East Asian populations in Figure 2.14 and formed 
a single cluster in Figure 2.15), which deviated from the Europe branch. This may possibly 
result from Finland’s unique language linkage. Not like other Europeans, Finns speak kind of 
Uralic language instead of an Indo-European language. The phylogenetic tree revealed that 
MIs with functions similar to those of SNPs are key to tracing the evolution of the genetic 
structure of human populations. 
 
Figure 2.18 - MDS of 26 populations based on all the 6,968 MIs. 
To further expose the undiscovered relationships of the MIs among the 26 populations, 
we performed principal component analysis (PCA) of the 26 populations with all the 6,968 
MIs. As shown in Figure 2.17, the PCA of MI patterns revealed that the 26 populations were 
divided into four groups according to the top two main components. This result indicated that 
the populations in same super-population were closer to each other. We found that African, 




represented genetic drift through human evolution or other factors. Unlike the other four super-
populations, the American populations are dispersed and do not form a distinct cluster. Our 
results are well consistent with the widespread pattern from SV PCA analysis. We also 
performed multidimensional scaling (MDS) analysis with all the 6,968 MIs displayed in 
Figure 2.18. Similar to the results in the PCA, the MDS result also shows that the populations 
in the same super-populations are closer compared with those in different super-populations. 
2.3.4 MIR sharing analysis among five super-populations 
 
Figure 2.19 - Venn diagram of all MIRs sharing results among the five super-
populations. 
Since the distinct variation pattern of each population may implicitly affect phenotype 
divergence among the population, it is significant to explore the common and distinct MIRs 




five super-populations. To further investigate the diversity and relationship of MI among the 
five super populations, we conducted an MIR sharing analysis with a Venn diagram by 
counting all the MIRs (Figure 2.19). We found that 76 MIRs were shared by all five super-
populations.   
 
Figure 2.20 - Venn diagram of MIR sharing results in only the gene regions according 
to the GENCODE database among the five super-populations. 
Furthermore, we used the MIRs located only in the genetic region in the Venn diagram 
(Figure 2.20), 34 MIRs within gene regions according to the GENCODE database were shared 
by all five super-populations (Figure 2.20). In addition, no MIR in the gene region was shared 
by the four super-populations, America, Europe, South Asia, and East Asia except the 34 MIRs 
that are shared by all five super-populations. However, any four of the super-populations, as 
long as Africa was included, shared at least one MIR in addition to the 34. This result suggests 




closer to African than to each other. Venn diagram also indicates that some MIs are shared 
among the five super-populations and the other MIs are private to one specific super-
population or private to a population. In general, each population has private MIs and common 
MIs shared with other populations in the same super-population. This result is also consistent 
with the SV polymorphism in the previous study. 
In the current study, we define “MIR hit” for an MIR as the number of MIs included 
within the MIR. Consequently most MIRs in gene regions were unique in every super-
population (i.e., singleton MIRs), especially for the Europe population. There was a total of 
1,008 singleton MIRs and 36 non-singleton MIRs. The full list of MIR hit counts in gene 
region among super-populations appears in Table 2.3. According to the results listed in Table 
2.3, the most recurrent non-singleton MIR in gene region had a hit of 8, and was in the super-
population of Africa. The next most recurrent MIR (hit = 7) was also in Africa. This may be 
due to the fact that Africa consisted of multi-ethnic groups. 



















East Asia 192 1 1 1 0 0 0 0 
Europe 388 4 0 1 0 0 0 0 
Africa 225 12 6 2 2 0 2 1 
America 91 1 0 0 0 0 0 0 
South Asia 112 2 0 0 0 0 0 0 


















ANKRD36 Africa 7 
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PRPSAP2 Africa 4 Osteosarcoma Intron Chr17 








PYY Europe 4 Obesity Intron Chr17 
Although the MIs in healthy individuals have not made an immediate impact or caused 
diseases directly at present, we infer that MI occurrences in gene regions rather than the 
intergenic regions are more likely to affect gene function, and thus potentially result in the 
phenotypic diversity of disease susceptibility among various populations in future. To 
investigate the potential association of MIs with gene function and human diseases among 
various populations, we conducted the analysis of the genes that are frequently affected by 




Table 2.3. We obtained the gene function through GeneCard (http://www.genecards.org/) as 
well as related reference studies and listed them in Table 2.4. As shown in Table 2.4, MIs do 
cause substitutions against the same position on the human reference genome hg19 [116] in the 
gene regions. Although it is not clear how these MIs in intron or exon (UTR) regions affect 
the functions of genes, it is reported that both UTRs and exon regions play an important role 
in translation and transcription [125,126].  
Table 2.5  Count of common MIs among seven non-human primates and five 
human super-populations. 
Name All MIs East Asia South Asia Europe Africa America 1KGP 
Chimpanzee 
(panTro4) 
2,284 12 11 7 14 11 20 
Gorilla 
(gorGor3) 
2,010 10 11 9 14 10 18 
Orangutan 
(ponAbe2) 
3,473 9 9 7 10 9 14 
Gibbon 
(nomLeu1) 
3,713 6 7 5 7 3 13 
Baboon 
(PapHam1) 
4,547 5 5 3 6 5 8 
Rhesus 
(rheMac3) 




4,214 2 2 2 2 2 2 
Total 24,476 49 49 35 58 44 82 
In addition, most of these genes listed in Table 2.3, are reported to be related with health. 
Among these genes, one named ANKRD, overlapped with the MIs in only African populations. 




we found gene ANK3, which overlapped with MIs in only East Asians, have been reported 
previously to be a risk factor for schizophrenia, a chronic and severe mental disorder, in Han 
Chinese[128], which may explain the only existence of MIs in ANK3 in East Asians. 
Furthermore, we compared the MIs in human with the seven closely related non-human 
primates (chimpanzee, gorilla, orangutan, gibbon, baboon, rhesus monkey, and squirrel 
monkey) to investigate the inheritance and evolution of MIs. By comparing MIs in the 
genomes of non-human primates against the hg19 [116] human reference genome and MIs 
detected in the genomes of the 1KGP super-populations, we discovered a larger number of 
MIs in Africa overlapping with the seven non-human primates. As shown in Table 2.5, the 
number of MIs shared by non-human primates and five super-populations are in the 
descending order: 58 shared with African, 49 with East Asian, 49 with South Asian, 35 with 
European. The higher overlapping ratio of MIs between the non-human primates and Africans 
might be due to that African inherited these shared MIs from the common ancestor of non-
human primates and human. Indeed, we inferred that after the Out-of-Africa geographic 
movement of modern human, Africa ancestral population would have spread the distribution 
of the most MIs, and partial of these MIs would survive in contemporary populations, resulting 
in the smaller MI number among the other four super-populations. However, further 





As we analyzed the MI count per individual among 26 populations, we found that PUR 
(Puerto Ricans from Puerto Rico) and ASW (Americans of African Ancestry in SW USA) 
have the most MIs per individual. These two populations with high-frequency MIs also have 
a high degree of admixture in the previous SNP study [115]. This suggests that admixture degree 
may potentially affect the MI count by multiple ancestral lineages among populations, which 
were also reported to affect genetic diversity by previous studies [129]. Specifically, ASW 
genome has been reported to come from three ancestral lineages with 75.9% of African, 21.3% 
of European, and 2.8% of Native American [ 130 ]. PUR, with a particular geographical 
stratification along the island and the ancestry of Amerinds, Spanish, and Africans, has the 
potential to enlarge the expected MI diversity [131,132]. As for the rest three populations with 
high-level MIs including YRI, CEU and JPT, the reasons for high-level of MIs may vary with 
more complex implications. We noticed that YRI was distinguished from other Africans with 
significant heterogeneity when the population structure was compared with other African 
populations in another study [133]. Although the admixture degree result showed that the 
admixture degree of CEU was not as high as PUR and ASW, it was reported that CEU 
descended from migrants originating from northern and western parts of Europe [134]. With the 
lowest MI count among the five populations, JPT was reported a noteworthy proportion of the 
special Jomon ancestry in the modern Japanese, which leads to JPT’s genetic features quite 
distinct from other East Asian populations although the admixture degree is not as high as 




of population structure and migration history are necessary to confirm the reasons for the high-
level of MIs in these five populations. 
In the phylogenetic analysis of the 26 populations, geographical distributions and 
migrations affected the MIs. African and American populations were clustered into a branch 
on the phylogenetic tree perhaps because African Americans are the largest racial minority [137] 
and a mixed heritage is common in America. Specifically, the populations on the East Coast 
of America and in Western Africa were clustered on another branch. This cluster may be due 
to the black slave trade from Western Africa to the East Coast of America [138]. The populations 
on the West Coast of America and in Eastern Africa were closer than other populations. This 
closeness is consistent with the migration of people from Eastern Africa to the West Coast of 
America [139]. We found that European and South Asian populations were clustered into one 
branch in Figure 2.16, which has also been reported in other studies focusing on copy number 
variations and retro-duplications [140]. The specificity of the Finnish population (FIN) can be 
interpreted in terms of multiple genetic components and demographic factors such as isolation, 
migration, and admixture, which are reflected in their distinctive distribution among the 
European populations in another study [141]. Moreover, our finding that PUR (Puerto Ricans 
from Puerto Rico) are closer to populations in East Asia is reasonable because some Peruvians 
are Asian immigrants [142].These MIs used in phylogenetic tree and PCA analysis could also 
be used to cluster different super-populations, showing that these MIs represented different 




populations are consistent with the corresponding migration history and ethnicity composition 
of these populations.  
We arranged the five super-populations in descending order of average number of MIs 
per individual as follows: Africa > America > Europe > South Asia > East Asia. Among these 
five super-populations, the average numbers of MIs per individual supported the “Out of 
Africa” hypothesis, which believed that humans originated in Africa, then recent Africans 
migrated to other continents. Scientists speculated that modern Africans first migrated to 
Eurasia, which is the continents of Europe and Asia considered together. In addition, the blood 
genetic distance of Africans and Europeans is smaller than that of Africans and Asians, which 
implies a closer relationship of Africa and Europe [143]. Specifically, as reported by Macaulay 
et al [144], the initial branch of the Asians from the southern dissemination pursued the Nile 
from the east of Africa, went towards north and aimed to get into Asia. When through the 
Sinai, the crowd branched, some shifted into Europe and the others went on heading into Asia. 
This assumption is based on the comparatively late date of the landing of modern humans in 
Europe. Through the process to East Asia, a small part of the African migrated along the 
Arabian Peninsula and India Cost in South Asia, and arrived at Australia finally [143, 144]. The 
high MI count in America is possibly be due to the African ancestry of these American 
populations and its complex population structure.  
It is known that long-term migration can cause genomic variations [145]. We inferred that 




four non-African super-populations, the Africans introduced some MIs into the ancestors of 
the other four super-populations. It is speculated that the differential coevolution of MI 
lineages with different but closely-related ancestral populations and subsequent MIs in parallel 
with the introgression of archaic alleles into the genomes of modern human ancestors may be 
largely responsible for the present-day variant counts of MIs in multiple populations. 
Therefore, our results may be evidence of the “Out of Africa” hypothesis.  
Evidence of the “Out of Africa” hypothesis also stems from a comparison between the 
MIs of non-human primates and those of humans. Africans shared the most MIs with the seven 
non-human primates, but the other four super-populations only shared a few. The higher 
overlapping ratio of MIs between the non-human primates and Africans might be due to that 
African inherited these shared MIs from the common ancestor of non-human primates and 
human in the ancient time. It may be assumed that, after the Out-of-Africa geographic 
movement of modern human, Africa ancestral population would have spread the distribution 
of the MIs which are shared with the seven non-human primates, and partial of these MIs 
would survive in contemporary populations. Indeed, the periodic genetic interchange among 
human super-populations, both in ways of frequent gene flow constrained by geographical 
distance and of population extension events causing interbreeding[On account of that not all 
of the MIs in African will be exchanged into the other four super-populations, smaller number 
of MIs survived among the other four super-populations. However, further sophisticated fossil 




GRM7, and DFNA5, all related to hearing[146-148] in both humans and non-human primates. 
This suggests that the MIs in these three genes may have existed in the common ancestors of 
humans and non-human primates and were conserved in some non-human primates and some 
human super-populations. Therefore, it may be that the super-populations that inherited the 
MIs may differ from others in their sense of hearing.  
The analysis also showed that some of the regions in the human reference genome hg19 
do not include complete information. Of the 76 MIs in the five super-populations, 34 
overlapped with genes, and 35 were also found in the seven non-human primates. Compared 
with the most recent common ancestor of the human population, hg19 may be inverted in the 
regions that overlap with the 34 MIs because such regions are conserved among close species. 
However, some of these regions have been reported as single-nucleotide variations because of 
the limited understanding of MIs. In addition, hg19 has been reported to contain rare alleles, 
according to the Genome Reference Consortium [149]. Accordingly, the reference of human 
MIs should be taken into account in updates of the reference of human assembly in the future 
studies. 
Here, we focused more on the effects of MIs on human evolution. However, as we 
analyzed the genes that overlapped with MIRs, we found that MIs may be associated with 
human health. Though the functions of the intron and UTR regions affected by MIs with 
limited samples in this dissertation are not clear yet by now, these MIs may potentially benefit 




super-population, especially those overlapped with gene regions, may increase the 
susceptibility of some diseases. With limited samples from healthy individuals in the 1KGP, 
MIs in this dissertation are possible candidates for future studies. Accordingly, more MIs from 
samples of diseases are needed to explore the correlation of MIs and human health. 
Nevertheless, we expect personalized medical information in the future can help us better 
understand the relationship of MIs and health, as well as unveil of disease mechanisms. 
2.5 Conclusions 
In this study, we made a comprehensive analysis of MIs on non-disease individuals from 
the 1KGP and seven non-human primate genomes, then built a landscape of human 
populations and explored the effect of MIs on human diversity, evolution and health. Applying 
the software MID[43]. for 26 human populations and searchUMI for alignments between the 
human and seven non-human primate genomes, respectively, we analyzed the 6,968 MIs 
detected in 1,937 individuals of the 26 populations from the 1KGP and the common 82 MIs 
among the seven non-human primate genomes and the 1,937 individuals. It is shown that the 
MIs from five super-populations (Africa, America, Europe, South Asia, and East Asia) reveal 
population structures at multiple levels and may affect individuals in several aspects. Firstly, 
the widespread MIs in human genomes greatly contribute to human diversity, which could be 
a result of geographical distribution and human migration. Secondly, the large-scale MIs are 




the MIs in particular super-populations, especially those overlapped with gene regions, are 
informative for understanding the association of health and genetic variations.  
To our knowledge, our study is the first to analyze MIs in humans on the population scale. 
In this dissertation, MIs are displayed in many levels including short reads, individual genomes, 
population-scale, and ancestry-scale. Furthermore, the MIRs supported by multiple short reads, 
individuals genomes, various populations will contribute to the concrete understanding of MIs. 
Our analysis of MIs with the 1KGP data improves our understanding of human genetic 
diversity and evolution. The comparative analysis of MIs at the population, super-population, 
and species scales are thus expected to contribute to further implementation of human 
evolutionary theory. Future large-scale sophisticated fossil data and archaeological materials 
for analyzing the age of MI polymorphism will be informative for understanding the behavior 
as genetic markers and better reconstructing the human evolution history. 
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CHAPTER 3  ANALYSIS OF MICRO-INVERSIONS IN 
CANCER GENOMES 
3.1 Introduction  
Many SV patterns have been observed by studies on cancer genomes. Besides, SV 
detection tools based on the high-throughput sequencing data permit researchers to single 
out the patterns of structural variations that characterize special type of cancers in recent 
years. These studies reflect that SVs are not restricted to one type cancer. Besides, studies 
show that the genomes of different cancers display various prevalence of variations on 
chromosomes, and regions of the genomes. Though many SVs don’t directly cause cancers, 
some could contribute to serious illness as a result of changing the function of regulatory 
regions such as enhancer elements and promoters [cl]. Other SVs may affect cancers by 
influencing the protein signal pathways. 
A few studies show that the cancer individuals of one type of cancer all have some 
SVs in unique genes. For example, two genes DICER1 and DROSHA are frequently found 
with copy number variations in non-small-cell lung cancer patients [cli]; the stem cell marker, 
SALL4 were often discovered in Asians with hepatocellular carcinoma [clii ]; Research 
shows that most pancreatic cancer patients have the somatic mutation on the gene KRAS 
[cliii ]; deletion of ETV6/RUNX1 gene was found in patients with acute lymphoblastic 
leukemia [ cliv ]; Reproducible copy number variations in MAPKAPK2 promoter were 
proved to have impact on lung cancer patients [clv]; and the gene DEFB4 in each sample 
with cervical cancer in the study of Abe et al. was identified with copy number variation[clvi]. 
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In consideration of that SVs in various types of cancers are likely to have distinct 
preferences of discrete gene regions, analyzing the genes with some frequent variations 
among numerous cancers is exclusively significant. In addition to the different SVs among 
various types of cancers, some common regions on the genome were found with highly-
unified SVs in many cancers. For example, it is reported that tumors were found with 
identical replicating sequences on the gnome [clvii,clviii]. In general, some variations occur in 
only one special type of cancer, but the other SVs are in common by multiple cancers. 
Although many studies have focused on the association of SVs and cancers previously, 
MIs have never been included in these analysis. Therefore, the research field of MIs in 
cancer genomes are still blank. In this part, we have conducted a thorough analysis of MIs 
in six cancers including 145 samples of esophageal cancer, 131 samples of bladder cancer, 
67 samples of hepatocellular carcinoma, 62 samples of lung cancer, 32 samples of prostate 
cancer, and 14 samples of pancreatic cancer from SRA database. 
3.2 Materials and methods 
The MI analysis in this part mainly includes collecting samples, detecting and 
annotating MIs, analyzing the chromosomes that MIs prefer to be located in, analyzing the 
top genes MIs frequently happen in each cancer and comparing MIs with SNPs which 
overlapped with MIs in the same genome regions. The pipeline for the whole analysis is 
displayed in Figure 3.1. The details of the materials and methods are described as follows: 
3.2.1 Sample collection 
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Besides the databases storing healthy individuals such as 1KGP, cancer genomic 
database also exist extensively such as Sequence Read Archive (SRA) database [19]. A 
comprehensive understanding of genomic variation and regulation of cancer could lead to 
a better understanding of cancer mechanisms and genomic manifestations [ clix ]. The 
analysis of variations in cancer genomes are helpful to drug sensitivity predictions based 
on heredity, lineage, and gene expression. Researches have shown that large-scale 
annotated aggregation of cancer sample information may contribute to clinical validation 
of anticancer agents, clinical prediction of drug response and the design of related cancer 
treatment plans, which may accelerate the pace of personalized cancer medicine [clx]. 
SRA database stores raw sequencing data and alignment information based on high-
throughput sequencing platforms, including Roche 454 GS System®, Illumina Genome 
Analyzer, Applied Biosystems SOLiD System, Helicos Heliscope, Complete Genomics, 
and Pacific Biosciences SMRT. One of the advantages of SRA is that it stores sequencing 
data not only healthy individuals but also cancer samples.  
The high-throughput sequencing data in SRA mainly includes two categories: whole 
genome sequencing (WGS) and whole exome sequencing (WES). Generally, WGS 
sequence the complete DNA of the whole genome at a single time. This process brings 
about sequencing all of the genome chromosomal DNA as well as DNA contained in the 
mitochondria and, for plants, in the chloroplast. Thus, whole genome sequencing is the 
most comprehensive approach to genome research. Genomic information could be used to 




The rapidly falling cost of sequencing and the increased ability to process large 
samples of data have made whole-genome sequencing the most powerful tool available to 
today's sequencers. However, WGS has its own limitation. For example, WGS is time 
consuming and the cost of WGS is really high compared with whole exome sequencing 
(WXS). Besides, since the WGS needs to cover all the sites on the genome, the sequencing 
depth is usually not high. WGS is often understood to be used to determine the human 
genome, but the scale and flexibility of high-throughput sequencing is such that it can be 
used efficiently in any species, such as animal husbandry, plants, disease-related 
microorganisms and non-human primates. In this part, the data used for analyzing cancer 
genomes are all WGS. 
It’s important to depend how cancer genome data be used for cancer biology and 
cancer therapy. With the advent of high-throughput sequencing technology, it’s possible to 
make comparative genomics analysis between clinical cancer patient and personalized 
individuals without diseases [clxi]. Indeed, people can better understand cancer genome 
characteristics, cancer causes and possible mechanisms.   
In this dissertation, we collected BAM files of the unmapped reads of 451 samples 
from SRA database. These samples are patients of 145 from esophageal cancer, 131 from 
bladder cancer, 67 from hepatocellular carcinoma, 62 from lung cancer, 32 from prostate 
cancer, 14 from pancreatic cancer. All the 145 Illumina samples are pair-end sequencing 
reads based on WGS. Each of these short reads is 151 bp. In addition, the samples for this 
part include both males and females with age of 51 to 70 years old.  Besides, we adopted 
the 1,937 normal individuals from the third phase of 1KGP, which were described in the 
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part of 2.1, as the control samples. These data allow for the comprehensive comparison of 
health cancer samples and healthy samples as well as samples of the six different cancers.  
3.2.2 MI detection and annotation 
Identical to detecting MIs from the individual genomes from 1KGP, we applied the 
tool MID [43] to identify MIs in the individuals of the six cancers. MID was set with default 
parameters: the anchor length was set at 18 bp, and the mismatches length was set at 2 bp. 
Then, MID remapped the total unmapped short reads to the human reference genome hg19. 
MID is a reliable tool proposed by our previous work, which is able to intensively detect 
MIs from bam files containing unmapped short reads with dynamic programming 
algorithm. Furthermore, MID is extremely perceptive to fine-scale MIs of which length are 
10 to 100 bp. Although some of the SV detection tools proposed in previous studies can 
also detect inversions, the length of the detected inversions are too large usually larger than 
one thousand base pairs, which are not comparable to the length of MIs (10 to 100 bp).  
After detecting MIs with MID, we annotated MIs with annotation files from 
GENCODE database based on hg19 coordinates. GENCODE is a genetic annotation 
database that identifies genetic characteristics through a series of computational analyses, 
manual annotations, and experimental results. GENCODE integrates a lot of gene 
information such as protein coding, long noncoding RNA (lncRNA), coding sequence 
(CDS) and is widely used in genome annotation. During this process of gene annotation in 
cancers, MIs were annotated as intergenic and genetic. In case that an MI was annotated as 
intergenic, it means this MI was in intergenic region and didn’t overlap with any gene 
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regions; if an MI was annotated as gene, it means this MI was overlapped with at least one 
gene of the human assemble hg19. 
 
Figure 3.1 - The pipeline of the analysis of MIs in cancers. 
3.2.3 Average MI count per Individual 
Considering that the sample number is different in the six cancers, the MI characteristics 
of the cancer genomes and the normal samples will be better displayed through the average 
count of MIs per individual in one cancer than the total MI number of each cancer or 
healthy group. To address this point, we define parameter pC  to represent the average 












 ,                                                    (1) 
In this evaluation, Ci means the count of MIs per individual, and Np means the total number 
of individuals in a cancer or the healthy group from 1KGP. 
3.2.4 Venn diagram analysis 
To further interrogate the diverse patterns of special genes overlapped with MIs 
among the six cancers, we performed a gene sharing analysis by counting all the genes 
overlapped with MIs in each cancer. Since the Venn diagram is only available for at most 
five categories, we removed pancreatic cancer with the least sample size of only 14 and 
included the rest five cancers including esophageal cancer, bladder cancer, prostate cancer, 
lung cancer, and hepatocellular carcinoma in this analysis. The process of conducting the 
Venn diagram is in a few steps. Firstly, we selected the MIs that were annotated as gene 
region as reported by the annotation files from GENCODE database. Then, we extracted 
the genes overlapped with these MIs in each of the five cancers. Next, we filtered these 
genes, removed the repeated genes, and obtained the unique genes. At last, we applied 
these unique genes to perform a Venn diagram to discover the shared common genes of 
the five cancers. 
3.2.5 Comparison with SNPs 
In consideration of the short length of MIs, we speculated that MI sites on the human 
genomes have been improperly reported by the previous studies as SNPs. Thus, we have 
downloaded the list of the exact sites of mutations in genes annotated in the Catalogue Of 
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Somatic Mutations In Cancer (COSMIC) database [clxii ], the largest somatic mutation 
depository to date, to see whether there is an overlap between MIs analyzed in this 
dissertation and the SNPs reported before. We got all the COSMIC coding point mutations 
from both targeted and genome wide screens from the recent release (v90). On account of 
that the SNPs from COSMIC are coordinated with the human reference genome hg38, we 
converted the genome coordinates from hg38 to hg 19 with the tool CrossMap [clxiii] with 
file option of vcf.  
3.3 Results 
In this part, we analyzed 451 samples from SRA database comprising six types of 
cancer including 145 samples from esophageal cancer, 131 samples from bladder cancer, 
67 samples from hepatocellular carcinoma, 62 samples from lung cancer, 32 samples from 
prostate cancer, and 14 samples from pancreatic cancer. With MID tool, we detected a total 
of 12,532 MIs, of which 5,995 (47.84%) overlapped with gene regions. Of the total 12,532 
MIs, 3,917 MIs were unique. In other words, the rest 8,615 MIs were repetitive to at least 
another MI in the 12,532 MIs. Besides, we included the 1,937 normal individual genomes 
from 1KGP as the control samples. As reported in the section of 1KGP analysis, which 
included healthy people genomes, we identified 6,968 MIs, of which 3,549 (50.93%) MIs 
were in gene regions. Of the 3,549 MIs in gene regions, only 370 (10.42%) were in exon 
regions. The comparison of MI distributions of cancer samples and healthy individuals 
implies that the possibility of MI occurrence in cancer genomes (12,532 MIs/451 samples) 
is much higher than that in healthy samples (6,968 MIs/1937 samples). However, the 
frequency of MIs in gene regions of both the cancer samples (47.84%) and healthy samples 
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(50.93%) is high. The details of MIs detected in the cancer genomes are shown in Table 
3.1. With all the samples detected in this part, we do the following MI analysis. 





MI-numa MI-uniqueb MI-genc MI-aved 
Esophageal cancer 145 4,873 1,042 2,224 33.61 
Bladder cancer 131 4,103 1,528 1,977 31.32 
Hepatocellular 
carcinoma 
67 359 304 208 5.36 
Lung cancer 62 977 976 519 15.76 
Prostate cancer 32 2,082 791 985 65.06 
Pancreatic cancer 14 138 118 82 9.86 
Total 451 12,532 3,917 5,995 27.79 
Healthy Samples 1,937 6,968 2,140 3,549 3.60 
a. The “MI-num” column illustrates the number of MIs for each cancer.  
b. The “MI-unique” column illustrates the number of unique MIs that are not overlapped with each 
other.  
c. The “MI-gen” column illustrates the number of MIs that overlap with genes for each cancer. 
d. The “MI-Ave” column illustrates the average number of MIs per individual in each cancer. 
3.3.1 MI distribution on chromosomes 
The MI distribution on human chromosomes in all the cancer genomes and the healthy 
genomes is shown in Figure 3.2. It is well known that human chromosomes are numbered 
in the decreasing order of chromosome length. For example, Chromosome 1 has the most 
base pairs and are the longest of all the 24 chromosomes. As shown in Figure 3.2, the MI 
count generally increased with the chromosome length increasing. This result is logical due 
to that longer chromosomes have more base pairs and more chance to make a mistake in 
the DNA replication. Thus, the MI occurrence frequency in longer chromosomes may 
increase. However, the MI number is not strictly linearly dependent to the chromosome 
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length. For example, the result in the Figure 3.2 shows that Chromosome 3, 6, 13, 19 in 
cancers performs differently with other chromosomes.  
 
Figure 3.2 - MI distribution among 24 chromosomes in cancer and healthy samples. 
The yellow bars represent MIs in cancer samples and the green bars represent MIs 
in normal individuals. 
Specifically, the MI number of Chromosome 3 is higher than that in Chromosome 2, 
while the Chromosome 2 have more base pairs than Chromosome 3. Chromosome 6, 13, 
and 19 have similar situations. Different with cancer genomes, the special chromosomes 
are 19, 17, 16, and 11 for the healthy individuals from 1KGP. To sum up, MIs of cancers 
and healthy individuals show different preferences across chromosomes. Besides, the 
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average MI number in each chromosome in cancer samples is extremely higher than that 
in healthy samples.  
In addition to the comparison of MI distribution on chromosomes between cancer and 
healthy samples, we also included the comparison of MI distribution among chromosomes 
in six cancers. The MI distributions among 24 chromosomes in the six cancers including 
esophageal cancer, bladder cancer, hepatocellular carcinoma, lung cancer, prostate cancer, 
and pancreatic cancer are shown in Figure 3.3. Roughly, MI count correlated with 
chromosome length in each type of cancer.  
The result in Figure 3.2A shows that Chromosome 6, 8, 13 are observed differently 
with other chromosomes in MIs of esophageal cancer. Specifically, Chromosome 8 has 
much fewer MIs than Chromosome 7 and even fewer MIs than Chromosome 9, but the 
Chromosome 8 have more base pairs than Chromosome 9. The situation is the same with 
Chromosome 13. However, the situation is different with Chromosome 6. Besides, there 
are several differences of the chromosomes which MIs prefer to be located in among the 
six cancers. 
Figure 3.3B implies that MIs from bladder cancer samples are less likely to happen 
on Chromosome 8 and more likely to occur on Chromosome 6 and 11. In addition, the 
result shows that the distribution of MIs among chromosomes in bladder cancer is very 





Figure 3.3 - MI distribution among 24 chromosomes in six cancers. (A) MI 
distribution among chromosomes in esophageal cancer. (B) MI distribution among 
chromosomes in bladder cancer. (C) MI distribution among chromosomes in 
hepatocellular carcinoma. (D) MI distribution among chromosomes in lung cancer. 
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(E) MI distribution among chromosomes in prostate cancer. (F) MI distribution 
among chromosomes in pancreatic cancer. 
Figure 3.3C shows that MIs from hepatocellular carcinoma samples are more likely 
to happen on Chromosome 6 and 7 and less likely to happen on Chromosome 4. Figure 
3.3D shows that MIs from lung cancer are more likely to happen on the Chromosome 6, 8, 
and 12. Figure 3.3E displays that MIs from prostate cancer are more possible to happen on 
the Chromosome 2, 6 and 14. Figure 3.3F implies that MIs from pancreatic cancers are 
more likely to happen on Chromosome 5 and 11, and less likely to happen on Chromosome 
2, 4 and 8. It should be noted that, only lung cancer and pancreatic cancer show higher 
number of MIs in Chromosome 1 than Chromosome 2. 
Besides, the MIs located on Chromosome 6 occurred more frequently in all the five 
cancers including esophageal cancer, bladder cancer, hepatocellular carcinoma, lung 
cancer, prostate cancer except only pancreatic cancer. In summary, MIs in the six cancers 
all show different prevalence across 24 chromosomes. The MI preferences for disparate 
chromosomes among the six cancers could provide a guidance for diagnosis and therapy 
on cancers in the future. Medical doctors should focus more on those chromosomes that 
MIs frequently occur.  
3.3.2 Average number of MIs per individual 
The error bar plot of the average number of MIs per individual in all the six cancers 
is displayed in Figure 3.4. In general, the average number of MIs per individual in healthy 
samples (1.89) from the 1KGP is much lower than that of any type of cancer (The lowest 
number of MIs per individual in six cancers is hepatocellular carcinoma with 5.36). 
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Additionally, there is a huge difference of the average number of MIs in different cancers. 
Specifically, the average number of MIs per individual varies from 5.36 to 21.98 in the six 
cancers. The average MI count in prostate cancer is the highest with 24.18, while the 
pancreatic cancer individuals have the lowest MI count per individual with 5.36. This 
analysis also displays that MIs occur more frequently in cancer samples than in healthy 
samples.  Moreover, the MI average number varies greatly from cancer to cancer. 
3.3.3 Venn diagram of genes overlapped with MIs 
 
Figure 3.4 - Average number of MIs among individuals with six cancers and normal 
individuals. 
To further interrogate the genes which are frequently found overlapped with MIs in 
the genomes of six cancers, we implemented a gene sharing analysis by the Venn diagram. 
 
 93 
Since the Venn diagram is only available for at most five categories, we removed 
pancreatic cancer with the least samples of 14 and included the rest five cancers including 
esophageal cancer, bladder cancer, prostate cancer, lung cancer, and hepatocellular 
carcinoma in this analysis. Pointedly, we applied the unique genes overlapped with MIs of 
the five cancers into this analysis.  
The Venn diagram of the shared genes by five cancers is shown in Figure 3.5. 
Generally, each cancer has more private genes of themselves than the ones shared by at 
least two cancers. Only three genes are shared in common by all the five cancers. The 
commonly shared three genes are AC079807.4, CNTNAP2, and EYS. AC079807.4. 
Interestingly, EYS gene was also found with MIs in healthy individual genomes from the 
1KGP, while CNTAP2 gene was only discovered in cancer genomes but not healthy 
genomes. Moreover, the protein expression of CNTNAP2 was reported as disease-specific 
(DSS) [clxiv]. Besides, though CNTNAP2 gene have not been studied as traditional cancer 
mutational targets, CNTNAP2 was reported to action as tumor suppressors since they 
exhibit expression loss in multiple types of tumor [clxv]. Considering that some MIs in 
cancer individuals may also exist in healthy samples, we will target more on the MIs 
discovered in only cancer samples, but not found in the healthy individual genomes in the 
next part. Besides, we speculate that MIs in healthy samples will not be deleterious to 




Figure 3.5 - Venn diagram of genes that overlap with MIs in individuals of five 
cancers. Esophageal, Bladder, Prostate, Hepatocellular, Lung, and Hepatocellular 
refers to esophageal cancer, bladder cancer, prostate cancer, lung cancer, and 
hepatocellular carcinoma individuals respectively. 
We also performed cluster analysis with all the MIs of the six cancers (Figure 3.6). 
As it’s shown in Figure 3.6, the six cancers were clustered into two branches, lung cancer 
and hepatocellular carcinoma into one branch and esophageal, bladder cancer, prostate 
cancer, and pancreatic cancer into another branch. Besides, the esophageal cancer and 




Figure 3.6 - Cluster result of the six cancers. Esophageal, Bladder, Prostate, 
Hepatocellular, Lung, Pancreatic, and Hepatocellular refers to esophageal cancer, 
bladder cancer, prostate cancer, lung cancer, pancreatic cancer, and hepatocellular 
carcinoma individuals respectively. 
3.3.4 Top genes overlapped with MIs 
We also summed up the top five genes in which MIs most frequently occurred among 
the healthy samples and the six cancers in Table 3.2 (A) and (B). We also listed the 
information if this gene with frequent MIs in cancer genomes also exist in healthy genomes. 
The top five genes that are most commonly presented with MIs in healthy samples are 
SLCA3A1, PREPL, SQSTM1, TNIK, and CTTNBP2. For all the six caners, the most 
frequent genes overlapped with MIs are SQSTM1, TNIK, CTTNBP2, NLRP4, RP11-
380P13.1. Among them, SQSTM1, TNIK, and CTTNBP2 appeared in both healthy and 
cancer genomes. TNIK was reported to be related with distant recurrence in patients of 
stage II and III colorectal cancer [clxvi]. Also, SQSTM1 was recorded to be related with 
gastric cancer [ clxvii ]. Furthermore, there is evidence supporting that CTTNBP2 are 
potentially related to prostate cancer [clxviii].   
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Table 3.2 - Top five genes overlapped with MIs. 
(A) Top five genes overlapped with MIs in normal samples. 
Rank Gene Name Number of MIs overlap 
1 SLC3A1 209 
2 PREPL 209 
3 SQSTM1 201 
4 TNIK 184 
5 CTTNBP2 136 
(B) Top five genes overlapped with MIs in all six cancers. 
Rank Gene Name Number of MIs overlap If in healthy samples 
1 SQSTM1 183 Yes 
2 TNIK 137 Yes 
3 CTTNBP2 132 Yes 
4 NLRP4 124 No 
5 RP11-380P13.1 112 Yes 
(C) Top five genes overlapped with MIs in esophageal cancer. 
Rank Gene Name Number of MIs overlap If in healthy samples 
1 SQSTM1 96 Yes 
2 CTTNBP2 65 Yes 
3 RERE 59 Yes 
4 NLRP4 59 No 
5 RP11-380P13.1 57 Yes 
(D) Top five genes overlapped with MIs in bladder cancer. 
Rank Gene Name Number of MIs overlap If in healthy samples 
1 TNIK 60 Yes 
2 SQSTM1 59 Yes 
3 CTTNBP2 46 Yes 
4 RP11-380P13.1 44 Yes 
5 RERE 42 Yes 
(E) Top five genes overlapped with MIs in hepatocellular carcinoma. 
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Table 3.2 (continued) 
Rank Gene Name Number of MIs overlap If in healthy samples 
1 TIAM2 9 No 
2 LPP 7 No 
3 AC002454.1 6 No 
4 TULP4 4 Yes 
5 AKNAD1 4 No 
(F) Top five genes overlapped with MIs in lung cancer. 
Rank Gene Name Number of MIs overlap If in healthy samples 
1 SORCS1 3 No 
2 AL163953.3 3 No 
3 RP11-420N3.2 3 No 
4 MAP3K13 2 No 
5 RPA3-AS1 2 No 
(G) Top five genes overlapped with MIs in prostate cancer. 
Rank Gene Name Number of MIs overlap If in healthy samples 
1 TNIK 23 Yes 
2 NLRP4 22 No 
3 SQSTM1 22 Yes 
4 SLC3A1 21 Yes 
5 FBXL7 20 Yes 
(H) Top five genes overlapped with MIs in pancreatic cancer. 
Rank Gene Name Number of MIs overlap If in healthy samples 
1 TNIK 4 Yes 
2 SQSTM1 4 Yes 
3 C12orf75 2 No 
4 ROCK1 2 Yes 
5 PRIM2 2 Yes 
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In summary, although the three genes all appeared with frequent MIs in both heathy 
genomes and cancer genomes, previous studies indicated that the three genes SQSTM1, 
TNIK, and CTTNBP2 displayed polymorphisms in different cancers and healthy 
individuals. Thus, these three genes should still be paid more attention to. It should be 
noted that, NLRP4 gene did not appear in the healthy individuals, but existed in cancer 
genomes. Not only that, NLPR4 was reported to be overexpressed in bladder carcinoma 
patients [clxix]. This result mean that the MIs in NLPR4 may have potential correlation with 
cancer occurrence.  
We also placed the top five genes in each of the six cancers including hepatocellular 
carcinoma, lung cancer, pancreatic cancer, bladder cancer and pancreatic cancer in Table 
3.2 (C) – (H). Generally speaking, the six cancers appeared different preferences for genes 
overlapped with frequent MIs. Besides the three genes of SQSTM1, TNIK, CTTNBP2 
which were in the top five genes of healthy samples, also appeared in most cancers. The 
top genes overlapped with MIs in hepatocellular and lung cancer almost didn’t appear in 
healthy individuals. This consequence may be due to the fact that not enough MIs 
overlapped with these genes compared with the number of MIs overlapped with genes in 
other cancers. More samples in the future may help solve this problem.  
Interestingly, TIAM2 gene in the top five genes of hepatocellular carcinoma was 
reported by previous studies as overexpressed in over 86% of hepatocellular carcinoma 
patients [clxx]. Thus, high number of MIs in TIAM2 may further explain the relation of 
hepatocellular carcinoma and TIAM2 gene. 
3.3.5 Comparison with SNPs 
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Considering the short length of MIs, we speculated that MI sites on the human 
genomes have been improperly reported by the previous studies as SNPs. To see the 
relationship of MIs and SNPs, we have downloaded the list of the exact sites of mutations 
in genes annotated in the Catalogue Of Somatic Mutations In Cancer (COSMIC) database, 
to see whether there is an overlap between MIs analyzed in this dissertation and the SNPs 
reported previously, 86,532 SNP coordinates were used to compare with the range of the 
unique 3,917MIs in the six cancers. A total of 139 SNPs in the coding regions were 
overlapped with MIs in this dissertation, which means that the 139 SNPs are possibly 
improperly reported by previous studies. Further studies need to re-examine whether the 
variations are SNPs or MIs. Table 3.3 list all the MIs that overlapped with the coding SNPs. 
The columns of Chr, MI start, MI end, Genes, C, and MI sequences represent the 
chromosomes that MIs and the overlapped SNPs located in, the overlapped MI start 
coordinates, MI end coordinates, the count of SNPs overlapped with MIs, and the MI 
sequence, respectively. 
Plenty of the genes listed in Table 3.3 have been demonstrated to have association 
with cancers. For example, FBXO43 gene have been demonstrated to be differentially 
expressed in hepatitis B virus-related hepatocellular carcinoma [clxxi]. Besides, another gene 
PGF was found with increase in expression in individuals with severe colorectal cancer 
[clxxii]. The MIs that overlapped with these cancer-related genes frequently are interesting 




The comparison of MI counts in cancer samples and healthy individuals implies that 
the possibility of MI occurrence in cancer genomes (12,532 MIs/451 samples) is much 
higher than that in healthy samples (6,968 MIs/1937 samples). This result is understandable 
considering that the genomes of cancer samples are more flexible compared with the 
reference genome hg 19, which is assembled with a few healthy individuals. However, the 
frequency of MIs in gene regions of both the cancer samples (47.84%) and healthy samples 
(50.93%) is high, which implies the MIs in the regulatory regions may also have an 
influence on cancer genomes. Besides, MIs in cancer genomes tend to happen more 
frequently in exon regions than in intron regions compared with those in health individual 
genomes. This result also indicates that the MIs in cancer genomes are more devastating 
than those in healthy people. The MIs in intron regions may also be related with 
carcinogenesis mechanism. Reports indicate that a number of regulators, such as initiators, 
terminators, repressors and enhancers, as well as cancer-related SVs, occur in the intron 
regions [clxxiii]. In addition, some SVs such as MIs are usually extended in the reverse 
complementary regions. In fact, Scacheri et al summarized the variations in non-coding 
regions and found that SVs in non-coding regions of the human genomes also play 
important roles in cancers [clxxiv].  
 Our results show that MI distributions among chromosomes in six cancers have both 
similarities and differences. Some cancers seem to share some common chromosomes. For 
example, the MIs are more likely to happen on Chromosome 6 in almost all the six cancer 
genomes. The MI preferences for divergent chromosomes among six cancers may provide 
a guidance for the remedy and diagnosis on the five cancers. More attention should be paid 
on the chromosomes that MIs frequently occur in the future. 
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The comparing analysis of the top genes overlapped with the frequently occurring MIs 
between healthy individual genomes and cancer genomes is important for the future studies 
of comparative genome analysis between cancer genomes and healthy genomes. 
Interestingly, NLRP4 gene was not in genes of healthy samples, but it did appear in the 
cancer genomes. Not only that, NLPR4 was reported to be overexpressed in bladder 
carcinoma patients. This result mean that the MIs in NLPR4 may have potential correlation 
with cancer occurrence.  
Generally speaking, the six cancers appeared different preferences for genes 
overlapped with frequent MIs. Besides the three genes of SQSTM1, TNIK, CTTNBP2 
which appeared in most cancers, each cancer has its own private preferred genes with MIs. 
The top genes overlapped with MIs in hepatocellular and lung cancer almost didn’t appear 
in healthy individuals. This consequence may be due to the fact that not enough MIs 
overlapped with these genes compared with the number of MIs overlapped with genes in 
other cancers. Interestingly, the TIAM2 gene in hepatocellular carcinoma was reported by 
previous studies as overexpressed in over 86% of hepatocellular carcinoma patients 
[170].Thus, the high number of MIs in TIAM2 may further explain the relation of 
hepatocellular carcinoma and TIAM2 gene. 
The comparison of the MIs with the corresponding SNPs show that that the locations 
of MIs on the human genomes detected in this dissertation may have been improperly 
reported by the previous studies as SNPs. Moreover, the cancer landscape reflected by only 
SNP data may not be complete, and our MI data may also be a good supplement to the 
current studies on the relationship of genome variation and cancers. 
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Table 3.3 - The list of MIs overlapped with SNPs. 
The columns of Chr, MI start, MI end, Genes, C, and MI sequences represent the chromosomes that MIs and the 
overlapped SNPs located in, the overlapped MI start coordinates, MI end coordinates, the count of SNPs overlapped with 
MIs, and the MI sequence, respectively. 
Chr MI start MI end Gene C MI sequence 
1 16,255,341 16,255,374 SPEN 4 AAAACCACGCAAGGCATGAGTTCCAGGCGGTTTT 
1 231,339,704 231,339,728 TRIM67 3 CCCCAGGATGTAGCCATCCACGGGG 
5 149,631,586 149,631,612 CAMK2A 2 TGGATATCCCTCCCCAGAAGTGCTGCG 
5 156,741,383 156,741,417 CYFIP2 3 TCAGACGAAGAGCTCGCGATACTCCTCGTCTGAC
T 
2 149,851,012 149,851,030 KIF5C 4 CTCTTCGCTGAGCGAGTCC 
2 179,499,110 179,499,138 TTN 16 GCTGAGGTGGAGGGCAAGAAGACCTCAGC 
3 182,871,613 182,871,642 LAMP3 3 CAGCTGCCCACAATACCACCCGCACAGCTG 
4 119,951,540 119,951,558 SYNPO2 6 GACTCTTCCTCCTTTCTTT 
4 155,252,824 155,252,851 DCHS2 7 TCTATGTCATAACCTGGGCAGATGGTGC 
6 25,973,440 25,973,473 TRIM38 2 CTTGGAAACATTGCACATAGTATGAAGTTCCAAG 
8 101,154,370 101,154,403 FBXO43 10 TTTGCAGAAACAGAGATTTTGAAGATGTCGCAAA 
9 91,628,348 91,628,369 SHC3 2 AGCAGTGACCTGGCCAGCACTG 
9 95,782,696 95,782,727 FGD3 2 CATCCCGGGCCACTGACTCACAGGCATGTCTG 
11 2,439,570 2,439,599 TRPM5 4 CCCCGTCTCAGAGGATCTCCAGGGCCGTGG 
11 104,815,538 104,815,565 CASP4 4 TTGAAACTCCAAGGGCCAAAGCTCAAAT 
11 129,772,306 129,772,340 PRDM10 5 CCAGGTCGAGCCACCTGCACACAGTGACTCCCTG
G 
11 134,051,038 134,051,068 NCAPD3 4 GCAGGTGTGTGGGGATGTACTCTCCACCTGC 
12 76,739,741 76,739,773 BBS10 3 ACTGCTTACCAATCAACCCTTGGTAAGCAGTCA 
14 75,416,174 75,416,204 PGF 12 GCTGGTGGACGTCGTGTCCGAGTACCCCAGC 
15 26,793,120 26,793,147 GABRB3 20 GCCCATGCCTCGAGAAGGGCATGGGCGA 
16 14,697,990 14,698,016 PARN 2 ATGCCAAAGAACAGGTAATTGGGCTAT 
16 70551522 70551541 COG4 4 TTCCCTGGCCAAGGTAAGGC 
17 45,896,450 45,896,477 OSBPL7 1 CTTCACCCCCAGATCACCAAGGGGAAGC 
17 77,758,078 77,758,099 CBX2 5 AGGCCGCACTTGTTGGTGGCCT 
19 38,376,145 38,376,176 WDR87 4 TTTTTCCAAGTGCCCATGCCTCTGTGGAAAAA 
20 62,738,141 62,738,163 NPBWR2 2 GAGCCCCTTGACAGCAGGGGCTC 
X 7,889,850 7,889,872 PNPLA4 3 TTCTTCCTCCCAGCGCTCACGAG 
X 70,316,615 70,316,635 FOXO4 2 CCCCAGGATTCCGGGCTGGGG 
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3.5  Conclusions 
In this chapter, we have generated a comprehensive analysis of MIs of 451 samples 
of six cancers, including 145 samples of esophageal cancer, 131 samples of bladder cancer, 
67 samples of hepatocellular carcinoma, 62 samples of lung cancer, 32 samples of prostate 
cancer, and 14 samples of pancreatic cancer from SRA database. We also used the 1,937 
healthy individuals from the 1KGP as the control samples. In all the cancer samples, we 
detected a total of 12,532 MIs, of which 5,995 (47.84%) overlapped with gene regions. Of 
the total 12,532 MIs, 3,917 MIs are unique. In other words, the rest 8,615 MIs are repetitive 
to at least one MI in the 12,532 MIs. 
We further analyzed the distribution of MIs in the six cancers among 24 chromosomes. 
The MI distributions among chromosomes among different cancers have both similarities 
and differences.  Additionally, we analyzed the average MI count per individual among 
each cancer and found that prostate cancer had the most MIs with about average 65 MIs 
per genome. In addition, we studied the top genes that overlapped with frequent MIs in six 
cancers and healthy samples. The results showed that the genes where MIs frequently 
occurred in different cancers were distinct. The MI preferences for divergent genes among 
six cancers could provide a navigation for the surgery and diagnosis of the six cancers. 
Besides, through the contrast of MIs detected in this dissertation and the SNPs in coding 
regions reported in the previous studies, an overlap was found between MIs and SNPs. Our 
MI data will be a good supplement to the current studies on the relationship of genome 
variation and cancers. 
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All these results above indicate that MIs have a potential association with cancer 
development. The comparative analysis of MIs in the six types of cancer will help further 
understand precision medicine on cancer individuals. At the same time, we hope our MI 
analysis will help future studies discover the disease mechanisms.  
One limitation of this study is the small sample size and the number of MIs. Due to 
the fact that MI count in each sample is not as high as that of SNPs, 12,532 MIs from 451 
samples were detected. As a next plan, we intend to include samples from more cancers 
and obtain more MIs to broaden the research cohort. Besides, we will focus more on the 
MIs that only exist in only one specific cancer. Thus, we will better explore the relationship 




CHAPTER 4  CONCLUSIONS AND FUTURE 
DIRECTIONS 
The advent of high-throughput sequencing have brought abundant sequencing data in 
recent years. The large amount of personal genome sequencing databases such as 1KGP 
and SRA have provided solid foundation for the SV analysis. At the same time, plenty of 
short reads generated by high-throughput sequencing have brought a series of problems 
and challenges. The current SV databases have the problem of incomplete and inconsistent 
SV information since the SVs are obtained through different tools and experiments. 
Accounting that there is currently no general guideline or tool for evaluating these SV sites, 
these SV-site information may not be absolutely reliable to a large extent. Besides, the 
studies about the analysis of the common or overlapped SVs among different genomes are 
lacked. This indicates that people’s understanding of genomic SVs is till limited. 
Undoubtedly, future researches are needed to yield a more accurate and reliable database 
of such SV analysis among different genomes. To achieve this goal and to enrich disease-
related genomic structural variation, future researches need to focus on how to construct a 
credible, accurate, genome-level overview of the human genome SVs.  
In this dissertation, MIs are defined as inversions that are shorter than 100 bp and 
larger than 10 bp. MIs are an important type of SVs, which could have significant influence 
on multiple diseases, population diversity and human evolution. In fact, although the 
researches and understanding of genomic SVs are developing rapidly, there are still 
considerable limitations of the field of MI studies. Thus, we made a comprehensive 
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analysis of the small-scale MIs in both healthy genomes and cancer genomes with a series 
of bioinformatics methods. For the analysis of MIs in healthy genomes, we made a 
landscape of MIs on non-disease individuals from the 1KGP based on high-throughput 
sequencing data. Besides, we included the MIs detected in seven non-human primate 
genomes including chimpanzee, gorilla, orangutan, gibbon, baboon, rhesus monkey, and 
squirrel monkey from UCSC Genome Browser to make a comparative genome analysis. 
With the software MID for 26 human populations and searchUMI for alignments between 
the human and seven non-human primate assembles, we obtained a total of 6,968 MIs in 
1,937 individuals of the 26 populations from the 1KGP and 24,476 MIs in the seven non-
human primate genomes. 
The MI results showed that the MIs from five super-populations (Africa, America, 
Europe, South Asia, and East Asia) revealed population structures at divergent levels and 
may affect individual genomes in several aspects. Specifically, the average number of MIs 
per genome in the five super-populations was in linear relationship with the descending 
order: Africa > America > Europe > South Asia > East Asia and this descending order also 
coincided with the “Out of Africa” hypothesis. We inferred that after the Out-of-Africa 
migration of modern human ancestors and hybridization among the four non-African 
super-populations, the ancient Africans introduced some MIs into the ancestors of the other 
four super-populations. Besides, the Africans had the most MIs shared with the seven non-
human primates among the five super-populations. The phylogenetic tree and PCA results 
of MIs showed that the widespread MIs in human genomes were related with geographical 
distribution and human migration. In general, our results of plenty of MIs are good 
supplements to existing evolution markers in reconstructing human evolutionary history 
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and the MIs in particular super-populations, especially those overlapped with gene regions, 
are informative for understanding the association of health and genetic variations. 
To further explore the roles of MIs in cancers, we detected and analyzed the MIs of 
451 samples based on the high-throughput sequencing data of six cancers, including 
esophageal cancer, hepatocellular carcinoma, lung cancer, pancreatic cancer, prostate 
cancer and bladder cancer from SRA database. We also applied the 1,937 samples from 
the 1KGP analysis as the control samples. The MI distribution among chromosomes in 
different cancers have both similarities and differences. When we counted the average MI 
number per individual, we found that the MI number in cancer genomes was much higher 
than that in healthy genomes. Besides, the genes in which MIs frequently occurred were 
distinct in six cancers. Besides, an overlap was found between the MIs detected in this 
dissertation and the SNPs reported in previous studies. 
Generally, our analysis of MIs in the six cancer genomes have shown that the amount 
of MIs in different cancers and the preference for chromosomes and genes are all different. 
All the results mentioned above indicate that MIs have a potential association with cancer 
development. We believe that our MI data will be a good supplement to the current studies 
on the relationship of genome variation and cancers. The comparative analysis of MIs in 
the six types of cancer may benefit for further employment of precision medicine on cancer 
individuals. In addition, our MI analysis may help future studies discover the disease 
mechanisms. In future, we plan to include more kinds of cancers and detect more MIs to 
enlarge the cohort of this study. Besides, we intend to include the analysis of the location 
of MIs on the chromosomes. For example, we could explore whether MIs tend to be near 
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telomere, centromeres and other special locations. Besides, it will also be significant to 
explore the GC content and the expression level of genes near the MIs. We believe these 
analyses will help reveal the mechanism of MIs. In addition, different cancers may have 
different preference for MI length distribution. We infer that whether MIs with different 
length are inherited or eliminated by evolution depends on different evolution pressure. 
Thus, we believed that these analysis will benefit analyzing the relationship of MIs, 
molecular evolution and genetic stability. 
In general, this dissertation has given a comprehensive analysis of the long-neglected 
MIs based on high-throughput sequencing data with a series of bioinformatics methods. 
The MI analysis results indicate that MIs have an undeniable significance on human 
diversity, evolution, environmental adaption, and diseases. We hope our analysis of MIs 
could improve our understanding of SVs in human diversity and evolution. Besides, we 
expect the comparative analysis of MIs in different cancer genomes could provide further 





APPENDIX A. THE LIST OF SAMPLES FROM 1KGP AND SRA   
The list of 1,932 samples from 1KGP classified by super-populations and populations 
East Asia (CHB, JPT, CHS, CDX, KHV): 
CHB includes 73 samples: 
NA18525, NA18526, NA18528, NA18530, NA18531, NA18532, NA18533, NA18534, 
NA18535, NA18536, NA18537, NA18538, NA18539, NA18541, NA18542, NA18543, 
NA18544, NA18545, NA18546, NA18547, NA18553, NA18560, NA18565, NA18567, 
NA18572, NA18574, NA18579, NA18591, NA18593, NA18596, NA18599, NA18602, 
NA18603, NA18605, NA18606, NA18608, NA18609, NA18611, NA18612, NA18613, 
NA18615, NA18616, NA18617, NA18618, NA18619, NA18620, NA18621, NA18622, 
NA18623, NA18624, NA18625, NA18626, NA18627, NA18628, NA18629, NA18630, 
NA18631, NA18632, NA18633, NA18634, NA18635, NA18636, NA18637, NA18639, 
NA18641, NA18642, NA18643, NA18644, NA18646, NA18647, NA18648, NA18748, 
NA18749. 
 
JPT includes 90 samples: 
NA18939, NA18942, NA18943, NA18944, NA18945, NA18946, NA18947, NA18948, 
NA18949, NA18950, NA18951, NA18953, NA18954, NA18956, NA18957, NA18959, 
NA18960, NA18961, NA18963, NA18964, NA18965, NA18966, NA18967, NA18968, 
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NA18970, NA18971, NA18972, NA18973, NA18974, NA18975, NA18976, NA18978, 
NA18979, NA18980, NA18981, NA18982, NA18983, NA18984, NA18986, NA18987, 
NA18988, NA18989, NA18990, NA18991, NA18993, NA18994, NA18995, NA18998, 
NA18999, NA19000, NA19001, NA19003, NA19004, NA19005, NA19006, NA19007, 
NA19009, NA19010, NA19011, NA19012, NA19054, NA19055, NA19056, NA19057, 
NA19058, NA19059, NA19060, NA19062, NA19063, NA19064, NA19065, NA19066, 
NA19067, NA19068, NA19070, NA19072, NA19074, NA19076, NA19077, NA19078, 
NA19079, NA19080, NA19082, NA19083, NA19085, NA19086, NA19087, NA19088, 
NA19090, NA19091. 
 
CHS includes 80 samples: 
HG00403, HG00404, HG00406, HG00407, HG00409, HG00410, HG00419, HG00421, 
HG00422, HG00428, HG00436, HG00437, HG00442, HG00443, HG00445, HG00446, 
HG00448, HG00449, HG00451, HG00452, HG00457, HG00458, HG00463, HG00464, 
HG00472, HG00473, HG00478, HG00479, HG00501, HG00525, HG00533, HG00534, 
HG00536, HG00537, HG00542, HG00543, HG00556, HG00557, HG00559, HG00560, 
HG00566, HG00577, HG00578, HG00580, HG00581, HG00583, HG00592, HG00593, 
HG00595, HG00598, HG00599, HG00611, HG00620, HG00622, HG00623, HG00625, 
HG00626, HG00628, HG00629, HG00631, HG00632, HG00634, HG00656, HG00657, 
HG00662, HG00663, HG00671, HG00674, HG00675, HG00683, HG00684, HG00692, 




CDX includes 62 samples: 
HG00844, HG00864, HG00867, HG00879, HG00956, HG00978, HG00982, HG01029, 
HG01031, HG01794, HG01795, HG01796, HG01797, HG01798, HG01799, HG01801, 
HG01802, HG01805, HG01806, HG01807, HG01810, HG01811, HG01812, HG01813, 
HG01815, HG02151, HG02152, HG02154, HG02164, HG02166, HG02178, HG02180, 
HG02181, HG02182, HG02184, HG02185, HG02186, HG02188, HG02190, HG02356, 
HG02367, HG02371, HG02373, HG02374, HG02375, HG02377, HG02380, HG02382, 
HG02386, HG02387, HG02388, HG02390, HG02392, HG02394, HG02395, HG02397, 
HG02401, HG02402, HG02406, HG02407, HG02408, HG02410. 
 
KHV includes 74 samples: 
HG01595, HG01597, HG01598, HG01599, HG01840, HG01842, HG01843, HG01844, 
HG01845, HG01846, HG01849, HG01850, HG01852, HG01855, HG01860, HG01861, 
HG01862, HG01863, HG01864, HG01865, HG01867, HG01868, HG01869, HG01870, 
HG01871, HG01872, HG01873, HG01874, HG01878, HG02016, HG02017, HG02019, 
HG02024, HG02025, HG02026, HG02028, HG02029, HG02035, HG02040, HG02046, 
HG02048, HG02057, HG02058, HG02060, HG02061, HG02064, HG02067, HG02069, 
HG02070, HG02072, HG02073, HG02075, HG02076, HG02079, HG02081, HG02082, 
HG02086, HG02113, HG02116, HG02121, HG02122, HG02127, HG02128, HG02133, 





Europe (CEU, TSI, FIN, GBR, IBS): 
CEU includes 80 samples: 
NA06984, NA06985, NA06986, NA06989, NA07000, NA07037, NA07048, NA07056, 
NA07346, NA07347, NA10847, NA11829, NA11831, NA11832, NA11881, NA11892, 
NA11893, NA11894, NA11918, NA11919, NA11920, NA11930, NA11931, NA11932, 
NA11933, NA11992, NA11994, NA12004, NA12005, NA12006, NA12044, NA12045, 
NA12046, NA12058, NA12144, NA12154, NA12155, NA12156, NA12234, NA12249, 
NA12272, NA12273, NA12275, NA12282, NA12283, NA12286, NA12340, NA12341, 
NA12342, NA12347, NA12348, NA12383, NA12399, NA12400, NA12413, NA12414, 
NA12489, NA12546, NA12716, NA12717, NA12718, NA12748, NA12749, NA12760, 
NA12762, NA12775, NA12776, NA12777, NA12778, NA12812, NA12814, NA12827, 
NA12829, NA12830, NA12842, NA12843, NA12872, NA12874, NA12889, NA12890. 
 
TSI includes 75 samples: 
NA20503, NA20504, NA20505, NA20506, NA20507, NA20508, NA20509, NA20510, 
NA20511, NA20512, NA20513, NA20514, NA20515, NA20516, NA20517, NA20520, 
NA20521, NA20522, NA20525, NA20526, NA20527, NA20528, NA20529, NA20530, 
NA20531, NA20532, NA20533, NA20535, NA20538, NA20539, NA20541, NA20543, 
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NA20544, NA20587, NA20588, NA20589, NA20752, NA20753, NA20754, NA20755, 
NA20756, NA20757, NA20759, NA20761, NA20762, NA20764, NA20766, NA20767, 
NA20768, NA20772, NA20775, NA20778, NA20783, NA20785, NA20786, NA20787, 
NA20790, NA20795, NA20797, NA20801, NA20803, NA20805, NA20806, NA20807, 
NA20809, NA20810, NA20813, NA20818, NA20819, NA20821, NA20822, NA20826, 
NA20827, NA20828, NA20832. 
 
FIN includes 77 samples: 
HG00171, HG00173, HG00174, HG00176, HG00177, HG00178, HG00179, HG00180, 
HG00181, HG00183, HG00185, HG00186, HG00188, HG00189, HG00190, HG00266, 
HG00267, HG00268, HG00269, HG00271, HG00272, HG00273, HG00274, HG00275, 
HG00276, HG00277, HG00278, HG00280, HG00281, HG00284, HG00285, HG00288, 
HG00290, HG00304, HG00306, HG00308, HG00309, HG00310, HG00311, HG00313, 
HG00319, HG00320, HG00324, HG00325, HG00326, HG00327, HG00329, HG00330, 
HG00332, HG00335, HG00336, HG00337, HG00341, HG00344, HG00345, HG00349, 
HG00350, HG00351, HG00353, HG00355, HG00356, HG00357, HG00358, HG00360, 
HG00361, HG00362, HG00364, HG00365, HG00367, HG00368, HG00371, HG00372, 
HG00378, HG00379, HG00382, HG00383, HG00384. 
 
GBR includes 74 samples: 
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HG00096, HG00099, HG00100, HG00101, HG00102, HG00103, HG00105, HG00106, 
HG00107, HG00110, HG00111, HG00112, HG00113, HG00114, HG00115, HG00116, 
HG00117, HG00118, HG00119, HG00120, HG00121, HG00122, HG00123, HG00124, 
HG00126, HG00127, HG00129, HG00131, HG00132, HG00133, HG00136, HG00137, 
HG00138, HG00139, HG00140, HG00141, HG00142, HG00143, HG00148, HG00149, 
HG00151, HG00154, HG00157, HG00160, HG00231, HG00233, HG00235, HG00236, 
HG00238, HG00239, HG00240, HG00242, HG00243, HG00244, HG00245, HG00246, 
HG00250, HG00251, HG00252, HG00253, HG00254, HG00255, HG00256, HG00258, 
HG00259, HG00260, HG00261, HG00262, HG00263, HG00264, HG00265, HG01334, 
HG01790, HG01791. 
 
IBS includes 70 samples: 
HG01501, HG01503, HG01506, HG01507, HG01509, HG01510, HG01512, HG01513, 
HG01515, HG01516, HG01518, HG01519, HG01521, HG01522, HG01524, HG01525, 
HG01527, HG01528, HG01530, HG01531, HG01536, HG01537, HG01606, HG01607, 
HG01607, HG01610, HG01619, HG01628, HG01630, HG01631, HG01632, HG01669, 
HG01670, HG01672, HG01676, HG01680, HG01682, HG01684, HG01685, HG01694, 
HG01695, HG01704, HG01705, HG01707, HG01708, HG01709, HG01710, HG01746, 
HG01747, HG01756, HG01757, HG01761, HG01762, HG01765, HG01766, HG01767, 
HG01768, HG01770, HG01775, HG01777, HG01779, HG01781, HG01784, HG01785, 




Africa (YRI, LWK, GWD, MSL, ESN, ASW, ACB): 
YRI includes 50 samples: 
NA18489, NA18499, NA18501, NA18502, NA18505, NA18508, NA18510, NA18517, 
NA18519, NA18858, NA18861, NA18870, NA18876, NA18877, NA18878, NA18879, 
NA18881, NA19093, NA19095, NA19096, NA19098, NA19099, NA19102, NA19108, 
NA19113, NA19117, NA19121, NA19137NA19138, NA19144, NA19146, NA19147, 
NA19149, NA19153, NA19159, NA19175, NA19184, NA19189, NA19201, NA19206, 
NA19207, NA19209, NA19210, NA19214, NA19222, NA19225, NA19238, NA19239 
NA19240, NA19257. 
 
LWK includes 83 samples: 
NA19017, NA19019, NA19023, NA19024, NA19025, NA19026, NA19028, NA19030, 
NA19031, NA19035, NA19036, NA19037, NA19038, NA19041, NA19042, NA19043, 
NA19307, NA19308, NA19310, NA19311, NA19313, NA19315, NA19316, NA19317, 
NA19318, NA19319, NA19320, NA19321, NA19323, NA19324, NA19327, NA19328, 
NA19331, NA19332, NA19334, NA19338, NA19346, NA19347, NA19350, NA19351, 
NA19355, NA19372, NA19374, NA19375, NA19377, NA19378, NA19385, NA19390, 
NA19391, NA19394, NA19397, NA19401, NA19403, NA19404, NA19429, NA19435, 
NA19437, NA19438, NA19439, NA19440, NA19443, NA19444, NA19445, NA19446, 
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NA19449, NA19451, NA19452, NA19453, NA19454, NA19455, NA19456, NA19461, 
NA19462, NA19463, NA19466, NA19467, NA19469, NA19470, NA19471, NA19472, 
NA19473, NA19474, NA19475. 
 
GWD includes 102 samples: 
HG02461, HG02462, HG02464, HG02465, HG02561, HG02562, HG02568, HG02570, 
HG02571, HG02573, HG02574, HG02582, HG02583, HG02585, HG02586, HG02588, 
HG02589, HG02594, HG02595, HG02610, HG02611, HG02613, HG02614, HG02620, 
HG02621, HG02623, HG02624, HG02628, HG02629, HG02634, HG02635, HG02642, 
HG02643, HG02645, HG02646, HG02666, HG02667, HG02675, HG02676, HG02678, 
HG02679, HG02702, HG02703, HG02715, HG02716, HG02721, HG02722, HG02756, 
HG02757, HG02760, HG02763, HG02768, HG02769, HG02771, HG02772, HG02798, 
HG02799, HG02804, HG02805, HG02807, HG02808, HG02810, HG02811, HG02813, 
HG02814, HG02816, HG02820, HG02837, HG02840, HG02851, HG02852, HG02860, 
HG02861, HG02870, HG02878, HG02879, HG02881, HG02882, HG02884, HG02885, 
HG02887, HG02888, HG02890, HG02891, HG02895, HG02896, HG03024, HG03027, 
HG03028, HG03039, HG03040, HG03045, HG03046, HG03048, HG03049, HG03240, 
HG03241, HG03246, HG03247, HG03258, HG03259, HG03539. 
 
MSL includes 81 samples: 
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HG03052, HG03054, HG03055, HG03057, HG03058, HG03060, HG03061, HG03063, 
HG03066, HG03069, HG03072, HG03073, HG03074, HG03078, HG03079, HG03081, 
HG03082, HG03084, HG03085, HG03088, HG03091, HG03095, HG03096, HG03097, 
HG03209, HG03212, HG03224, HG03225, HG03376, HG03378, HG03380, HG03382, 
HG03385, HG03388, HG03391, HG03394, HG03397, HG03401, HG03410, HG03419, 
HG03428, HG03432, HG03433, HG03436, HG03437, HG03439, HG03442, HG03445, 
HG03446, HG03449, HG03451, HG03452, HG03455, HG03457, HG03458, HG03460, 
HG03461, HG03464, HG03469, HG03470, HG03472, HG03473, HG03476, HG03478, 
HG03479, HG03484, HG03485, HG03547, HG03548, HG03556, HG03557, HG03558, 
HG03559, HG03563, HG03567, HG03571, HG03572, HG03575, HG03577, HG03578, 
HG03583. 
 
ESN includes 87 samples: 
HG02922, HG02923, HG02944, HG02946, HG02947, HG02952, HG02968, HG02970, 
HG02973, HG02974, HG02976, HG02977, HG02979, HG02981, HG03099, HG03100, 
HG03103, HG03105, HG03108, HG03109, HG03111, HG03112, HG03114, HG03115, 
HG03117, HG03118, HG03120, HG03121, HG03123, HG03124, HG03126, HG03127, 
HG03129, HG03130, HG03130, HG03133, HG03135, HG03136, HG03139, HG03159, 
HG03160, HG03162, HG03163, HG03166, HG03168, HG03169, HG03172, HG03175, 
HG03189, HG03190, HG03195, HG03196, HG03198, HG03265, HG03267, HG03270, 
HG03271, HG03279, HG03280, HG03291, HG03294, HG03295, HG03297, HG03298, 
HG03301, HG03303, HG03304, HG03311, HG03313, HG03342, HG03343, HG0335, 
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HG03352, HG03354, HG03363, HG03367, HG03369, HG03370, HG03372, HG03499, 
HG03511, HG03514, HG03515, HG03517, HG03518, HG03520, HG03521. 
 
ASW includes 58 samples: 
NA19625, NA19700, NA19701, NA19703, NA19704, NA19707, NA19711, NA19712, 
NA19713, NA19818, NA19819, NA19834, NA19835, NA19900, NA19901, NA19904, 
NA19908, NA19909, NA19914, NA19916, NA19917, NA19920, NA19921, NA19923, 
NA19982, NA19984, NA19985, NA20126, NA20127, NA20276, NA20278, NA20281, 
NA20282, NA20287, NA20289, NA20291, NA20294, NA20296, NA20299, NA20314, 
NA20317, NA20318, NA20322, NA20332. 
 
ACB includes 81 samples: 
HG01879, HG01880, HG01882, HG01883, HG01885, HG01886, HG01889, HG01890, 
HG01894, HG01896, HG01912, HG01914, HG01915, HG01985, HG01986, HG01989, 
HG01990, HG02009, HG02010, HG02012, HG02014, HG02051, HG02052, HG02053, 
HG02095, HG02107, HG02108, HG02111, HG02143, HG02144, HG02255, HG02282, 
HG02283, HG02284, HG02307, HG02308, HG02309, HG02314, HG02315, HG02317, 
HG02318, HG02322, HG02323, HG02325, HG02330, HG02332, HG02339, HG02419, 
HG02427, HG02429, HG02433, HG02439, HG02442, HG02445, HG02449, HG02450, 
HG02455, HG02470, HG02471, HG02476, HG02477, HG02479, HG02481, HG02484, 
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HG02485, HG02489, HG02497, HG02501, HG02502, HG02505, HG02511, HG02536, 
HG02537, HG02541, HG02545, HG02546, HG02549, HG02554, HG02557, HG02558, 
HG02580. 
 
America (MXL, PUR, CLM, PEL) 
MXL includes 55 samples: 
NA19648, NA19649, NA19651, NA19652, NA19654, NA19657, NA19661, NA19663, 
NA19669, NA19676, NA19678, NA19679, NA19682, NA19684, NA19685, NA19719, 
NA19720, NA19722, NA19723, NA19725, NA19726, NA19728, NA19729, NA19731, 
NA19732, NA19734, NA19735, NA19741, NA19746, NA19747, NA19749, NA19750, 
NA19752, NA19755, NA19756, NA19758, NA19759, NA19761, NA19762, NA19764, 
NA19770l, NA19773, NA19774, NA19776, NA19777, NA19779, NA19780, NA19782, 
NA19783, NA19785, NA19786, NA19788, NA19789, NA19792, NA19795. 
 
PUR includes 39 samples: 
HG00731, HG00732, HG00733, HG00742, HG00743, HG01048, HG01058, HG01063, 
HG01064, HG01077, HG01085, HG01086, HG01088, HG01089, HG01092, HG01095, 
HG01104, HG01161, HG01162, HG01164, HG01188, HG01200, HG01205, HG01286, 
HG01303, HG01305, HG01308, HG01311, HG01312, HG01325, HG01393, HG01395, 




CLM includes 70 samples: 
HG01112, HG01113, HG01119, HG01121, HG01122, HG01124, HG01125, HG01133, 
HG01134, HG01136, HG01137, HG01140, HG01142, HG01149, HG01250, HG01251, 
HG01253, HG01254, HG01256, HG01257, HG01259, HG01260, HG01269, HG01271, 
HG01272, HG01277, HG01280, HG01284, HG01341, HG01342, HG01344, HG01345, 
HG01348, HG01350, HG01351, HG01353, HG01360, HG01362, HG01363, HG01366, 
HG01369, HG01372, HG01375, HG01378, HG01384, HG01431, HG01432, HG01435, 
HG01438, HG01441, HG01443, HG01444, HG01455, HG01461, HG01462, HG01464, 
HG01468, HG01474, HG01479, HG01485, HG01486, HG01488, HG01491, HG01494, 
HG01495, HG01497, HG01498, HG01550, HG01551, HG01556. 
 
PEL includes 63 samples: 
HG01565, HG01577, HG01578, HG01917, HG01918, HG01920, HG01923, HG01926, 
HG01927, HG01932, HG01933, HG01935, HG01938, HG01939, HG01941, HG01942, 
HG01944, HG01945, HG01947, HG01948, HG01951, HG01953, HG01954, HG01967, 
HG01968, HG01970, HG01971, HG01973, HG01974, HG01976, HG01977, HG01979, 
HG01982, HG01992, HG01997, HG02002, HG02003, HG02008, HG02089, HG02090, 
HG02104, HG02105, HG02146, HG02150, HG02252, HG02260, HG02265, HG02271, 
HG02274, HG02275, HG02277, HG02278, HG02285, HG02291, HG02292, HG02298, 




South Asia (GIH, PJL, BEB, STU, ITU): 
GIH includes 83 samples: 
NA20845, NA20846, NA20847, NA20849, NA20850, NA20852, NA20853, NA20858, 
NA20859, NA20862, NA20863, NA20864, NA20867, NA20868, NA20869, NA20870, 
NA20871, NA20872, NA20877, NA20878, NA20881, NA20882, NA20884, NA20885, 
NA20886, NA20887, NA20888, NA20889, NA20890, NA20892, NA20893, NA20894, 
NA20895, NA20896, NA20897, NA20898, NA20899, NA20900, NA20901, NA20902, 
NA20904, NA20905, NA20906, NA20908, NA20910, NA20911, NA21086, NA21087, 
NA21088, NA21089, NA21090, NA21091, NA21092, NA21093, NA21094, NA21095, 
NA21098, NA21099, NA21100, NA21102, NA21103, NA21104, NA21105, NA21106, 
NA21107, NA21108, NA21110, NA21114, NA21115, NA21118, NA21119, NA21124, 
NA21125, NA21126, NA21127, NA21128, NA21129, NA21130, NA21133, NA21135, 
NA21137, NA21141, NA21143. 
 
PJL includes 85 samples: 
HG01583, HG01586, HG01589, HG01593, HG02490, HG02491, HG02493, HG02494, 
HG02597, HG02600, HG02601, HG02603, HG02648, HG02649, HG02651, HG02654, 
HG02655, HG02657, HG02658, HG02660, HG02661, HG02681, HG02682, HG02684, 
HG02685, HG02687, HG02688, HG02690, HG02694, HG02696, HG02697, HG02699, 
 
 122 
HG02700, HG02724, HG02725, HG02727, HG02728, HG02731, HG02733, HG02734, 
HG02737, HG02778, HG02780, HG02783, HG02784, HG02786, HG02787, HG02789, 
HG02790, HG02792, HG02793, HG03016, HG03018, HG03019, HG03021, HG03022, 
HG03229, HG03234, HG03237, HG03238, HG03491, HG03619, HG03624, HG03625, 
HG03629, HG03631, HG03634, HG03636, HG03640, HG03649, HG03652, HG03653, 
HG03660, HG03663, HG03667, HG03668, HG03702, HG03703, HG03705, HG03706, 
HG03708, HG03709, HG03762, HG03765, HG03767. 
 
BEB includes 68 samples: 
HG03006, HG03007, HG03585, HG03589, HG03594, HG03595, HG03600, HG03604, 
HG03607, HG03615, HG03616, HG03793, HG03796, HG03800, HG03802, HG03803, 
HG03805, HG03808, HG03812, HG03814, HG03815, HG03821, HG03823, HG03824, 
HG03826, HG03829, HG03830, HG03832, HG03902, HG03905, HG03907, HG03908, 
HG03910, HG03913, HG03914, HG03917, HG03919, HG03922, HG03925, HG03926, 
HG03931, HG03937, HG03940, HG03941, HG04131, HG04134, HG04140, HG04141, 
HG04146, HG04152, HG04153, HG04155, HG04158, HG04161, HG04162, HG04164, 
HG04171, HG04173, HG04176, HG04177, HG04180, HG04182, HG04183, HG04185, 
HG04186, HG04188, HG04189, HG04195.  
 
STU includes 91 samples: 
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HG03642, HG03643, HG03644, HG03646, HG03672, HG03673, HG03679, HG03680, 
HG03681, HG03684, HG03685, HG03686, HG03687, HG03689, HG03690, HG03691, 
HG03692, HG03693, HG03695, HG03697,HG03698, HG03733, HG03736, HG03740, 
HG03741, HG03743, HG03745, HG03746, HG03750, HG03752, HG03753, HG03754, 
HG03755, HG03756, HG03757, HG03760, HG03836, HG03837, HG03838, HG03844, 
HG03848, HG03849, HG03850, HG03851, HG03854, HG03856, HG03857, HG03858, 
HG03884, HG03885, HG03886, HG03887, HG03888, HG03890, HG03894, HG03895, 
HG03896, HG03897, HG03898, HG03900, HG03943, HG03944, HG03947, HG03948, 
HG03949, HG03950, HG03953, HG03955, HG03985, HG03986, HG03989, HG03990, 
HG03991, HG03995, HG03998, HG03999, HG04003, HG04006, HG04029, HG04033, 
HG04035, HG04038, HG04039, HG04042, HG04047, HG04075, HG04099, HG04100, 
HG04107, HG04227, HG04229. 
 
ITU includes 86 samples: 
HG03713, HG03714, HG03715, HG03716, HG03717, HG03722, HG03727, HG03729, 
HG03730, HG03731, HG03770, HG03771, HG03772, HG03773, HG03774, HG03775, 
HG03778, HG03779, HG03781, HG03784, HG03785, HG03786, HG03787, HG03788, 
HG03789, HG03790, HG03861, HG03862, HG03863, HG03864, HG03866, HG03867, 
HG03869, HG03870, HG03871, HG03872, HG03873, HG03874, HG03875, HG03882, 
HG03960, HG03963, HG03965, HG03967, HG03968, HG03969, HG03971, HG03973, 
HG03974, HG03976, HG03977, HG03978, HG04001, HG04002, HG04014, HG04015, 
HG04018, HG04019, HG04020, HG04022, HG04023, HG04025, HG04054, HG04056, 
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HG04059, HG04060, HG04061, HG04062, HG04063, HG04070, HG04076, HG04080, 
HG04090, HG04093, HG04094, HG04096, HG04098, HG04118, HG04200, HG04202, 
HG04206, HG04212, HG04219, HG04225, HG04235, HG04238. 
 
The list of 451 samples from SRA classified by cancer types 
Esophageal cancer includes 145 samples: 
SRR1056623, SRR1056628, SRR1056629, SRR1056630, SRR1056631, SRR1056632, 
SRR1056633, SRR1056634, SRR1056635, SRR1056636, SRR1056637, SRR1056638, 
SRR1056639, SRR1056640, SRR1056641, SRR1056642, SRR1056643, SRR1056644, 
SRR1056645, SRR1056646, SRR1056647, SRR1056648, SRR1056649, SRR1056650, 
SRR1056651, SRR1056652, SRR1056653, SRR1056654, SRR1056655, SRR1056656, 
SRR1056657, SRR1056658, SRR1056659, SRR1056660, SRR1056661, SRR1056662, 
SRR1056663, SRR1056664, SRR1056665, SRR1056666, SRR1056667, SRR1056668, 
SRR1056669, SRR1056670, SRR1056671, SRR1056672, SRR1056673, SRR1056674, 
SRR1056675, SRR1056676, SRR1056677, SRR1056679, SRR1056680, SRR1056681, 
SRR1056682, SRR1056683, SRR1056684, SRR1056685, SRR1056686, SRR1056687, 
SRR1056688, SRR1056689, SRR1056690, SRR1056691, SRR1056692, SRR1056693, 
SRR1056694, SRR1056695, SRR1056696, SRR1056697, SRR1056698, SRR1056699, 
SRR1056703, SRR1056705, SRR1056706, SRR1056708, SRR1056710, SRR1056711, 
SRR1056712, SRR1056713, SRR1056715, SRR1056721, SRR1056722, SRR1056723, 
SRR1056724, SRR1056725, SRR1056726, SRR1056727, SRR1056728, SRR1056729, 
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SRR1056730, SRR1056731, SRR1056732, SRR1056733, SRR1056734, SRR1056735, 
SRR1056736, SRR1056737, SRR1056738, SRR1056739, SRR1056740, SRR1056741, 
SRR1056742, SRR1056743, SRR1056744, SRR1056745, SRR1056747, SRR1056748, 
SRR1056749, SRR1056750, SRR1056751, SRR1056752, SRR1056753, SRR1056754, 
SRR1056755, SRR1056756, SRR1056757, SRR1056758, SRR1056759, SRR1056760, 
SRR1056761, SRR1056762, SRR1056763, SRR1056764, SRR1056765, SRR1056766, 
SRR1056767, SRR1056768, SRR1056769, SRR1056770, SRR1056771, SRR1056772, 
SRR1056773, SRR1056774, SRR1056775, SRR1056776, SRR1056777, SRR1056778, 
SRR1056779, SRR1056780, SRR1056781, SRR1056782, SRR1056783, SRR1056784, 
SRR1056785. 
 
Bladder cancer includes 131 samples: 
SRR645164, SRR645165, SRR645166, SRR645167, SRR645168, SRR645169, 
SRR645170, SRR645171, SRR645172, SRR645173, SRR645174, SRR645175, 
SRR645176, SRR645177, SRR645178, SRR645179, SRR645180, SRR645181, 
SRR645182, SRR645183, SRR645184, SRR645185, SRR645186, SRR645187, 
SRR645188, SRR645189, SRR645190, SRR645191, SRR645192, SRR645193, 
SRR645194, SRR645201, SRR645203, SRR645205, SRR645207, SRR645209, 
SRR645213, SRR645214, SRR645216, SRR645218, SRR645220, SRR645222, 
SRR645224, SRR645226, SRR645227, SRR645229, SRR645231, SRR645233, 
SRR645235, SRR645237, SRR645239, SRR645241, SRR645243, SRR645245, 
SRR645247, SRR645249, SRR645253, SRR645255, SRR645257, SRR645259, 
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SRR645264, SRR645267, SRR645269, SRR645270, SRR645272, SRR645274, 
SRR645276, SRR645278, SRR645281, SRR645283, SRR645284, SRR645285, 
SRR645286, SRR645287, SRR645288, SRR645289, SRR645290, SRR645291, 
SRR645292, SRR645293, SRR645294, SRR645295, SRR645296, SRR645297, 
SRR645298, SRR645299, SRR645300, SRR645302, SRR645305, SRR645306, 
SRR645307, SRR645309, SRR645310, SRR645311, SRR645312, SRR645313, 
SRR645314, SRR645315, SRR645317, SRR645318, SRR645320, SRR645322, 
SRR645323, SRR645324, SRR645326, SRR645328, SRR645330, SRR645332, 
SRR645335, SRR645338, SRR645341, SRR645343, SRR645345, SRR645347, 
SRR645348, SRR645349, SRR645351, SRR645352, SRR645353, SRR645355, 
SRR645357, SRR645359, SRR645362, SRR645364, SRR645365, SRR645366, 
SRR645368, SRR645370, SRR645372, SRR645373, SRR645374. 
 
Hepatocellular carcinoma includes 67 samples: 
ERR232258, ERR232259, ERR232260, ERR232261, ERR232262, ERR232263, 
ERR232264, ERR232265, ERR232266, ERR232267, ERR232268, ERR232269, 
ERR232270, ERR232271, ERR232272, ERR232273, ERR232274, ERR232275, 
ERR232276, ERR232277, ERR232278, ERR232279, SRR2049021, SRR2049022, 
SRR2157816, SRR2157817, SRR2157818, SRR2157821, SRR2157822, SRR2157823, 
SRR2157824, SRR2157825, SRR2157826, SRR2157827, SRR2157828, SRR2157829, 
SRR2157831, SRR2157832, SRR2157833, SRR2157834, SRR2157835, SRR2157836, 
SRR2157837, SRR2157838, SRR2157839, SRR2157842, SRR2157843, SRR2157844, 
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SRR2157845, SRR2157846, SRR2157848, SRR2157849, SRR2157850, SRR2157851, 
SRR2157853, SRR2157854, SRR2157855, SRR2157856, SRR2157857, SRR2157859, 
SRR2157860, SRR2157861, SRR2157862, SRR2157863, SRR2157864, SRR2157867, 
SRR5296488. 
 
Lung cancer includes 62 samples: 
SRR975195, SRR975201, SRR975209, SRR975213, SRR975215, SRR975217, 
SRR975219, SRR975221, SRR975225, SRR975229, SRR975233, SRR975235, 
SRR975237, SRR975239, SRR975241, SRR975243, SRR975245, SRR975249, 
SRR975251, SRR975253, SRR975255, SRR975257, SRR975261, SRR975262, 
SRR975263, SRR975264, SRR975265, SRR975272, SRR975274, SRR975276, 
SRR975282, SRR975284, SRR975286, SRR975288, SRR975290, SRR975292, 
SRR975294, SRR975296, SRR975304, SRR975306, SRR975308, SRR975310, 
SRR975318, SRR975320, SRR975322, SRR975323, SRR975324, SRR975325, 
SRR975327, SRR975328, SRR975329, SRR975330, SRR975331, SRR975333, 
SRR975334, SRR975335, SRR975336, SRR975337, SRR975338, SRR975339, 
SRR975341, SRR981030. 
 
Prostate cancer includes 32 samples: 
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ERR532450, ERR532451, ERR532458, ERR532459, ERR532460, ERR532461, 
ERR532462, ERR532465, ERR532503, ERR532504, ERR532505, ERR532522, 
ERR532523, ERR532524, ERR532525, ERR532526, ERR532527, ERR532528, 
ERR532529, ERR532530, ERR532531, ERR532532, ERR532533, ERR532534, 
ERR532535, ERR532536, ERR532537, ERR532538, ERR532539, ERR532540, 
ERR532541, ERR532542. 
 
Pancreatic cancer includes 14 samples: 
ERR232239, ERR232240, ERR232241, ERR232242, ERR232243, ERR232244, 
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